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Abstract
Cardiovascular diseases (CVD), including atherosclerosis CVD (ASCVD), are
multifactorial diseases that present a major economic and social burden worldwide.
Tremendous efforts have been made to understand traditional risk factors for ASCVD,
but these risk factors account for only about half of all cases of ASCVD. It remains
a critical need to identify nontraditional risk factors (e.g., genetic variants, genes)
contributing to ASCVD. Further, incorporating functional knowledge in prediction
models have the potential to reveal pathways associated with disease risk. We propose
Bayesian hierarchical factor analysis models that associate multiple omics data, pre-
dict a clinical outcome, allow for prior functional information, and can accommodate
clinical covariates. The models, motivated by available data and the need for other
risk factors of ASCVD, are used for the integrative analysis of clinical, demographic,
and multi-omics data to identify genetic variants, genes, and gene pathways poten-
tially contributing to 10-year ASCVD risk in healthy adults. Our findings revealed
several genetic variants, genes and gene pathways that were highly associated with
ASCVD risk. Interestingly, some of these have been implicated in CVD risk. The
others could be explored for their potential roles in CVD. Our findings underscore
the merit in joint association and prediction models.
Keywords: Bayesian variable selection, cardiovascular disease, Factor Analysis, biological
information, joint association and prediction, integrative analysis
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1 Introduction
Cardiovascular diseases (CVD) including atherosclerosis CVD (ASCVD) are multifactorial,
and are caused by a combination of many factors such as genetic, biological, and environ-
mental factors. Many research applications and methods continue to demonstrate that a
better understanding of the pathobiology of CVD and other complex diseases necessitates
analysis techniques that go beyond the use of established traditional factors to one that in-
tegrate clinical and demographic data with molecular and/or functional data. For instance,
in a recent CVD research, the authors in (Benson et al., 2018) integrated genomics data
with CVD-risk associated proteins in human plasma and they identified many genetic vari-
ants (not previously described in the literature) which, on average, accounted for 3 times
the amount of variation in CVD explained by common clinical factors, such as age, sex, and
diabetes mellitus (Benson et al., 2018). Given that environmental risk factors for ASCVD
(e.g., age, gender, hypertension) account for only half of all cases of ASCVD (Bartels et al.,
2012), it remains a critical need to identify other biomarkers contributing to ASCVD. It
is also recognized that leveraging existing sources of biological information including gene
pathways can guide the selection of clinically meaningful biomarkers, and reveal pathways
associated with disease risk. In this study, we build models for associating multiple omics
data and simultaneously predicting a clinical outcome while considering prior functional
information. The models are motivated by, and are used for, the integrative analysis of
multi-omics and clinical data from the Emory Predictive Health Institute, where the goal
is to identify genetic variants, genes, and gene pathways potentially contributing to 10-year
ASCVD risk in healthy patients.
Our approach builds and extends recent research on joint integrative analysis and pre-
diction/classification methods (Kan et al., 2015; Luo et al., 2016; Li and Li, 2018; Safo
et al., 2019). Unlike two step approaches– integrative analysis followed by prediction or
classification– these joint methods link the problem of assessing associations between mul-
tiple omics data to the problem of predicting or classifying a clinical outcome. The goal
is then to identify linear combinations of variables from each omics data that are asso-
ciated and are also predictive of a clinical outcome. For instance, the authors in (Luo
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et al., 2016; Li and Li, 2018; Safo et al., 2019) combined canonical correlation analysis with
classification or regression methods for the purpose of predicting a binary or continuous
response. Luo et al. (2016), used a regression formulation of canonical correlation anal-
ysis (CCA) and proposed a joint method for obtaining canonical correlation vectors and
predicting an outcome from the canonical correlation vectors. The authors in (Safo et al.,
2019) proposed a joint association and classification method that combines CCA and linear
discriminant analysis, and uses the normalized Laplacian of a graph to smooth the rows of
the discriminant vectors from each omics data. This approach encourages predictors that
are connected and behave similarly to be selected or neglected together. These joint asso-
ciation and prediction methods have largely been developed from a frequentist perspective.
While there exist Bayesian factor analysis or CCA methods to integrate multi-omics data
types (Mo et al., 2018; Klami et al., 2013), we are not aware of any Bayesian method that
has been developed for joint association and prediction of multiple data types. Mo et al.
(2018) extended icluster into a Bayesian framework, and Klami et al. (2013) developed a
Bayesian CCA model by imposing a group-wise sparsity for inter-battery factor analysis
(IBFA).
In the present work, we extend current frequentist approach for integrative analysis
and prediction methods to the Bayesian setup. Our contributions are multi-fold. First, we
adopt a factor analysis (FA) approach to integrate multiple data types as done in (Shen
et al., 2009, 2013; Klami et al., 2013). This allows us to reduce simultaneously the dimen-
sion of each data type to a shared component with a much reduced number of features (or
components). On the other hand, our formulation of the problem is different from exist-
ing methods as it is defined in a Bayesian hierarchical setting which has the flexibility to
incorporate other functional information through prior distributions. Our approach uses
ideas from Bayesian sparse group selection to identify simultaneously active components
and important features within components using two nested layers of binary latent indica-
tors. Second, our approach is more general; we are able to account for the active shared
components as well as the individual latent components for each data type. Third, we
incorporate in a unified procedure, clinical responses that are associated with the shared
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components, allowing us to evaluate the predictive performance of the shared components.
Moreover, our formulation makes it easy to include other covariates without enforcing spar-
sity on their corresponding coefficients. Including other available covariates may inform the
shared components, which in turn may result in better predictive performance of the shared
components. Fourth, unlike most integrative methods that use FA, our prior distributions
can be extended to incorporate external grouping information; this allows us to determine
most important groups of features that are associated with important components. In-
corporating prior knowledge about grouping information has the potential of identifying
functionally meaningful variables (or network of variables) within each data type for im-
proved prediction performance of the response variable. In our estimation, we implement
a Markov Chain Monte Carlo (MCMC) algorithm for posterior inference that employs a
partially collapsed Gibbs sampling (van Dyk and Park, 2008) to sample the latent variables
and the loadings.
1.1 Motivating Application
There is an increased interest in identifying “nontraditional” risk factors (e.g., genes, genetic
variants) that can predict CVD and ASCVD. This is partly so because CVD has become
one of the costliest chronic disease, and continue to be the leading cause of death in the
U.S. (AHA, 2016). It is projected that nearly half of the U.S. population will have some
form of cardiovascular disease by 2035 and will cost the economy about $2 billion/day in
medical costs (AHA, 2016). There have been significant efforts in understanding the risk
factors associated with ASCVD, but research suggests that the environmental risk factors
for ASCVD (e.g., age, gender, hypertension) account for only half of all cases of ASCVD
(Bartels et al., 2012). Finding other risk factors of ASCVD and CVD unexplained by
traditional risk factors is important and potentially can serve as targets for treatment.
We integrate gene expression, genomics, and/or clinical data from the Emory University
and Georgia Tech Predictive Health Institute (PHI) study to identify potential biomarkers
contributing to 10-year ASCVD risk among healthy patients. The PHI study, which began
in 2005, is a longitudinal study of healthy employees of Emory University and Georgia
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Tech aimed at collecting health factors that could be used to recognize, maintain, and
optimize health rather than to treat disease. The goal of the PHI, the need to identify
other biomarkers of atherosclerosis cardiovascular diseases, and the data available from PHI
(multi-omics, clinical, demographic data), motivate our development of Bayesian methods
for associating multiple omics data and simultaneously predicting a clinical outcome while
accommodating prior functional information and clinical covariates.
The rest of the paper is organized as follows. In Section 2, we present the formulation
of the model approach. In Section 3, we describe our MCMC algorithm, present how to
evaluate our prediction performance, and we set hyperparameters of prior distributions.
In Section 4, we evaluate and compare our methodology using simulated data. Section
5 shows the application to atherosclerosis disease using both mRNA expression and SNP
information. Finally, we conclude our manuscript in Section 6.
2 Model formulation
Our primary goal is to define an integrative approach that combines multiple data types
and incorporates clinical covariates, response variables, and external grouping information.
In Section 2.1, we introduce the Factor analysis model that relates data types. We then
adopt a Bayesian variable selection technique in Section 2.2 to select active components and
their corresponding important features. We show how we incorporate grouping information
in Section 2.3.
2.1 Factor analysis model for integrating multiple data types and
clinical outcome
We assume that M (-omics) data types are available: X(m) = (x
(m)
ij )n×pm , where x
(m)
ij is
the measure of subject i on the feature j for data type m = 1, ...,M . A factor analysis
model for the M data types can be written as
X(m) = UA(m) +E(m), for m = 1, ...,M (1)
U ∼N (0, Inr) and E(m) ∼ N (0,Ψ(m))
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Here, Inr is the identity matrix of size nr. A
(m) is a r×pm coefficient matrix for data type
m with each row representing the factor loadings for components l = 1, ..., r. U is a n× r
matrix of latent variables that connects the M sets of models, thus inducing dependencies
among the data types. The latent variable is intended to explain the correlations across
the data types and E(m) is the error that explains the remaining variability unique to each
data type. The integrated data matrix (X(1), ...,X(M)) is then multivariate normal with
mean zero and covariance matrix Σ = ATA+ Ψ, where A = (A(1), ...,A(M)) and Ψ is the
diagonal block matrix of Ψ(m), m = 1, ...,M . As it is commonly done in factor analysis, we
assume Ψ(m) = Diag(σ
2(m)
1 , σ
2(m)
2 , ...., σ
2(m)
pm )⊗ In where σ2(m)j is the variance of feature j in
data set m. Model (1) is also called the Gaussian latent variable model. This model has
been extensively used for integrative clustering of multiple genomic datasets (Shen et al.,
2009, 2013; Chalise et al., 2014)
In this paper, we are interested in examining the association between the two sets of
features and performing predictive modeling of the response in an integrative way. Hence,
in addition to model (1), we treat the clinical outcome yn×1 as another variable set, and
is related to feature matrices X(1), ...,X(M) through the latent variables U . Thus, the
clinical equation can be written as y = X(0) = α0 +UA
(0) +E(0), where A(0) is a coefficient
vector of the effect component l, l = 1, . . . , r, has on the outcome; α0 is the intercept and
E(0) ∼ N (0, σ2(0)In) is the error term. We also assume that there is another data type
m = M + 1 which corresponds to the set of clinical covariates.
2.2 Bayesian variable selection using latent binary variables
To determine active components for each data type (including the outcome), we define an
r-binary latent variable vector, γ(m) = (γ
(m)
1 , , ..., γ
(m)
r ), given by γ
(m)
l = 1 if component
l = 1, ..., r is active in data type m and 0 otherwise for m = 0, 1, ...,M + 1. We assume
that for m = M + 1, γ
(M+1)
l = 1 for every l so that all components are potentially active
for clinical covariates.
We are not only interested in selecting the active components but we also want to
identify variables that significantly contribute to active components. Unlike the single
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layer of indicators used in the group-wise sparsity for inter-battery factor analysis (IBFA)
(Klami et al., 2013), we use two nested layers of binary indicators to denote whether a
component or a variable is selected or not. A similar idea was recently used for Bayesian
sparse group selection in regression models (Chen et al., 2016). At the component level,
for every m = 1, ...,M , γ(m) indicates which components are active for data type m. At
the variable level, η
(m)
j = (η
(m)
1j , ..., η
(m)
rj ) is an indicator vector for variables in the lth
component. Specifically, η
(m)
lj = 1 if feature j is selected in component l in data type m.
The prior distribution for the component indicator, γ
(m)
l , is the Bernoulli distribution with
parameter qm. In the lth component, the prior distribution of η
(m)
lj is dependent on the
indicator γ
(m)
l and is defined as
η
(m)
lj |γ(m)l ∼ (1− γ(m)l )δ0 + γ(m)l Bernouilli(qη), (2)
where Bernouilli(qη) is the Bernoulli distribution with probability qη. Thus, if the lth
component is not active, then η
(m)
lj = 0 for all j. We note that η
(m)
lj = 1 for every l and
m = 0,M +1 i.e the response variable and clinical covariates will be always included in the
model. To infer a sparse matrix Am, that is whether the a
(m)
lj entry in A
m is important
or not, we impose the following sparsity-inducing prior on the matrix elements given the
indicators η
(m)
lj and γ
(m)
l
a
(m)
lj |γ(m)l , η(m)lj ∼ (1− γ(m)l )δ0 + γ(m)l [(1− η(m)lj )δ0 + η(m)lj N (0, (τ (m)lj )2σ2(m)j )] (3)
∼ (1− γ(m)l η(m)lj )δ0 + γ(m)l η(m)lj N (0, (τ (m)lj )2σ2(m)j ).
Thus, if the jth variable in the active lth component is selected, then the prior of a
(m)
lj is
a normal distribution with zero mean and variance (τ
(m)
lj )
2σ
2(m)
j . Otherwise the coefficient
a
(m)
lj is equal to 0. When m = 0, the feature X
(0) is now the outcome and η
(0)
l1 = γ
(0)
l .
The prior distribution of the residual variance σ
2(m)
j is an inverse Gamma distribution,
σ
2(m)
j ∼ IG(a0, b0). Finally, we assume that γ(m)l ∼ Bernouilli(q(m)) and q(m) follows a Beta
distribution Beta(a, b).
Our method encompasses three different scenarios: i) each component is shared across
all data types (including the response) i.e. γ
(m)
l = 1 for every m = 0, 1, 2, . . . ,M,M+1 and
l = 1, ..., r. This scenario only accounts for the joint variation between the data types, and
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is assumed in standard CCA methods for high dimensional data integration such as (Witten
and Tibshirani, 2009; Luo et al., 2016; Safo et al., 2018) ii) none of the r components is
shared across data types i.e.
M⋂
m=0
{l = 1, ..., r; γ(m)l = 1} = ∅. This scenario would be similar
to the standard factor analysis for each data set independently, and accounts only for the
individual variations explained for each data set. iii) some components are only shared
across the data sets. Hence, our method can capture the amount of joint structure and
individual structure of the data sets. Our method then encompasses the Bayesian CCA and
the JIVE (Joint and Individual variation explained) methods introduced respectively by
Klami et al. (2013) and Lock et al. (2013). For instance, assume we have 2 other data types
(besides response and clinical covariates), r = 4 components, the first two components are
shared (i.e γ
(m)
1 = γ
(m)
2 = 1, for every m) and, components 3 and 4 are only associated
respectively with data types 1 and 2 (i.e. γ
(1)
3 = γ
(2)
4 = 1 and γ
(2)
3 = γ
(1)
4 = 0). The models
for data types 1 and 2 can then be written asX(1) = UA(1)+E(1) = U1,2A
(1)
1,2+U3A
(1)
3 +E
(1)
and X(2) = UA(2) +E(2) = U1,2A
(2)
1,2 +U4A
(2)
4 +E
(2), where U1,2 = (U1,U2) (resp. A1,2) is
the matrix of the first two components of U = (U1,U2,U3,U4) (resp. A). In this example,
U1,2 is the shared component, and U3 and U4 can be considered as the individual latent
structures for data types 2 and 3 respectively.
2.3 Incorporating grouping information through prior distribu-
tions
In this section, we present how we incorporate known group structures of the M data
types through prior distributions. For that, we introduce a design/loading matrix P (m) =
(κ
(m)
jk )(pm×Km) consisting of Km columns of dummy variables coding for group membership,
for every m = 1, ...,M . More specifically, κ
(m)
jk = 1 if marker j from data type m belongs to
group k = 1, ..., Km, and 0 otherwise. Here we assume that this matrix can be retrieved from
external scientific knowledge. For instance, genes can be grouped using KEGG pathway
information or other pathway/network information (Qiu, 2013). Similarly, SNPs can be
grouped using their corresponding genes.
In order to incorporate the grouping information P (m), we assume an additional layer
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from the prior of the factor loadings A(m). More formally, we incorporate the grouping
information through the prior distributions of (τ
(m)
lj )
2 as follows
(τ
(m)
lj )
2|λ(m)lj ∼ Exp((λ(m)lj )2) (4)
(λ
(m)
lj )
2|b(m)l· ∼ Γ(α, b(m)l0 + P (m)Tj b(m)l· ), (5)
where P
(m)T
j denotes the j-th row of the matrix P
(m) and Γ(α, β) denotes the gamma distri-
bution with shape α and rate β. The vector b
(m)
l· = (b
(m)
lk )Km represents the coefficient effects
of the groups. The intercept bl0 can be regarded as a global shrinkage hyper-parameter
determining the baseline level of shrinkage. From equation (5), each (λ
(m)
lj )
2 is indepen-
dently assigned a gamma distribution with expected value E((λ
(m)
lj )
2) = α
b
(m)
l0 +P
(m)T
j b
(m)
l·
=
α
bl0+
∑
k κ
(m)
jk b
(m)
lk
. By integrating out (λ
(m)
lj )
2, the marginal prior of a non-zero loading a
(m)
lj is
defined by
p(a
(m)
lj ) =
α + 1
2σ
2(m)
j
(bl0 +
∑
k
κ
(m)
jk b
(m)
lk )
α
(
|a(m)lj |
σ
(m)
j
+ bl0 +
∑
k
κ
(m)
jk b
(m)
lk
)−α−1
(6)
The parameter b
(m)
lk is assumed to be non-negative in order to reduce the amount of
shrinkage attributable to the k-th important group. Hence, higher values b
(m)
lk give more
evidence for group information by increasing the effect of features belonging to group
k (see Figure 2.1 for an illustration of the marginal prior (6) of a loading). A similar
prior construction was considered by Rockova and Lesaffre (2014) to incorporate grouping
information in the context of regression models.
For the purpose to determine important groups that contribute to the formation of
active components, we define another (r×Km)-latent binary matrix variableR(m) = (r(m)lk ),
where r
(m)
lk = 1 if group (or pathway) k contributes to active component l, and 0 otherwise.
The prior of b
(m)
lk is then dependent on R
(m) and will be defined as
b
(m)
lk |r(m)lk ∼ (1− r(m)lk )δ0 + r(m)lk Γ(αb, βb)
r
(m)
lk |qr ∼ Bernoulli(qr)
We finally assume that the intercept b
(m)
l0 follows also a Gamma Γ(α0, βb). Correlations
between significant features within the same group are captured through the prior of the
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Figure 2.1: Marginal prior densities of a
(m)
lj for different values of b
(m)
l1 while other parameters
are fixed: σ2 = 1, bl0 = 0.4, α = 1.
penalty parameter λ
(m)
lj (see prior (5)). For instance, if features 1 and 2 both belong to the
same group, the joint marginal distribution of (λ21, λ
2
2) (after integrating out b0 + b1) is
p(λ21, λ
2
2) ∝ g(λ21, λ22) = (λ21λ22)α−1(βb + λ21 + λ22)−(2α+α0+αb).
Figure 2.2 draws the contour plots of g(λ21, λ
2
2) for four combinations of (αb, βb) = (1, 1),
(1, 2), (2, 1), (2, 2) with α0 = 1 and α = 2. As we would expect, as βb increases and/or αb
decreases, λ21 and λ
2
2 tend to have a stronger correlation, translating to a higher probability
to have similar values.
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Figure 2.2: Contour plots of the marginal prior density of λ21 and λ
2
2 for 4 different combi-
nations of αb and βb.
3 Posterior inference and prediction
For posterior inference, our primary interest is in the estimation of the active component
and feature selection indicator variables γ(m), η(m), and the loadings A(m) = (a
(m)
lj ). We
implement a Markov Chain Monte Carlo (MCMC) algorithm for posterior inference that
employs a partially collapsed Gibbs sampling (van Dyk and Park, 2008) to sample the
binary matrices and the loadings. In fact, to sample γ(m), η(m) given the other parame-
ters, we integrate out all the loadings A(m), and we use a Metropolis-Hastings step. We
then sample the loadings from its full conditional distributions. In Section 7 in the web
supplementary material, we present the conditional distributions used to update all the
parameters. We outline the steps of our MCMC algorithm hereafter.
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1. Initialize the parameters τ
(2m)
lj with 1, b
(m)
l0 with 0.1, and the other parameters by
their prior distributions.
2. Sample (γ(m), η(m)) using a Metropolis-Hastings step as described in web supplemen-
tary material Section 7.1.
3. Sample the loading matrices A(m), σ
2(m)
j , τ
(2m)
lj and λ
(2m)
lj form their full conditionals
distributions as defined in Sections 7.2-7.4 of the web supplementary material.
4. Sample r
(m)
lk and b
(m)
lk simultaneously using a Metropolis-Hastings step as described
in Section 7.5 of the web supplementary material.
Prediction: Given a model {γ(m), η(m),m = 1, ...,M}, we estimate the loadingsA form =
0, 1, ...,M+1 as aˆ
(m)
·j(η) = σˆ
2(m)
j (U¯
T
(γ)U¯(γ) +Inγ )
−1U¯T(γ)x
(m)
·j , the posterior mode of A(η), where
σˆ
2(m)
j and U¯(γ) are the means of the values sampled in the course of the MCMC algorithm.
Let X
(m)
new, m = 1, ...,M be the vector of features of a new individual. The latent value U
of a new individual for a given model {γ(m), η(m),m = 1, ...,M}, is estimated as Uˆnew,(γ) =
(Aˆ(η)D(σˆ
−2)AˆT(η) + Ir)
-1Aˆ(η)D(σˆ
−2)xnew·, where xnew· = (x
(1)
new·, ...,x
(M)
new,·,x
(M+1)
new,· ), D(σˆ−2)
is the diagonal matrix with elements {σˆ2(m)j ,m = 1, ..,M + 1, j = 1, ..., pm} on the di-
agonal, and Aˆ(η) = (Aˆ
(1)
(η), ..., Aˆ
(M)
(η) , Aˆ
(M+1)
(η) ). Hence the predictive response is computed
using a Bayesian model averaging approach (Hoeting et al., 1999) as follows yˆnew = αˆ0 +∑
N ,γ Uˆnew,(γ)Aˆ
(0)
(η)p(γ,N |U¯(γ),X) where αˆ0 is the posterior mean of the intercept α0.
Hyperparameter settings
For both simulations and observed data analysis, we set the hyperparameters as follows.
We set r = 4 as the maximum number of active components. We note that a larger number
can be set as our approach is able to select active components for each data through the
indicators γ(m). We present in Tables 8.4 and 8.5 in the web supplementary material a
sensitivity analysis for the parameter r. We obtain similar results with larger r. We set
qη = 0.05, the prior probability to select features for a specific component as we expect
that a small number of features are active in every component (refer to Tables 8.2 and
8.3 in web supplementary material for a sensitivity analysis of qη). We set a = b = 1,
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hyperparameters of q(m) (prior probability to select a feature) and qr (prior probability to
select a group) which follow each a beta distribution (a, b). We set a0 = b0 = 0.01 to have
a vague gamma prior on σ
2(m)
j . We set α = 1, the scale hyperparameter of λ
2(m)
lj . Last,
we set αb = βb = 1, hyperparameters of group effects b
(m)
lk (when r
(m)
lk = 1) that follow a
gamma distribution (αb, βb).
4 Simulation studies
We consider three main scenarios to assess the performance of the proposed methods. In
each scenario, there are two data typesX(1) ∈ <n×p1 andX(2) ∈ <n×p2 simulated according
to equation (1), and a single continuous response y ∈ <n×1. We simulate each scenario to
have r = 4 latent components. The scenarios differ by how many components are shared
across data types. In the first scenario, the four latent components are shared across all two
data types. The first two shared components affect the response. In the second scenario,
none of the r components is shared across the two data types. Components 1 and 2 are
unique to data type 1, and components 3 and 4 are unique to data type 2. Components 1
and 3 are associated with the response in this scenario. In the third scenario, two of the
components (1 and 2) are shared, component 3 is unique to data type 1, and component 4
is unique to data type 2. The response is associated with components 1, 3, 4. We partition
the covariance matrix in each data type into signal and noise; signal contain variables that
are correlated and contribute to the response, while noise variables are uncorrelated and
unimportant. In each scenario, we generate 20 Monte Carlo data sets for each data type.
4.1 Scenario One: Each component is shared across all data types
This Scenario is assumed in standard CCA methods for high dimensional data integration.
We simulate two data types (X(1),X(2)), X(1) ∈ <n×p1 , and X(2) ∈ <n×p2 , (n, p1, p2) =
(200, 500, 500) according to equation (1) as follows. Without loss of generality, we let the
first 100 variables form the networks or groups in X(1) and X(2). Within each data type
there are 10 main variables, each connected to 9 variables. The resulting network has
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100 variables and edges, and p1 − 100 and p2 − 100 singletons in X(1) and X(2) respec-
tively. The network structure in each data type is captured by the covariance matrices
Ψ(1) =
 Ψ¯100×100 0
0 Ip1−100
 , Ψ(2) =
 Ψ¯100×100 0
0 Ip2−100
 . Here, Ψ¯ is block diagonal
with 10 blocks of size 10, between-block correlation 0 and within each block there is a 9×9
compound symmetric submatrix with correlation 0.49 describing the correlation structure
of the connected variables. The correlation between a main and a connecting variable is
0.7. We let the p1 − 100 and p2 − 100 singletons form one group that do not contribute
to the outcome and association between X(1) and X(2). A(1) ∈ <r×p1 and A(2) ∈ <r×p2
are pre-specified true sparse factor loading matrices that describe the variables that are
important and associated with the outcome. We consider different pre-specifications of
A(1) and A(2) to capture the relationship between networks, and variables and networks
that are associated with the outcome. Figures 4.1(a)-4.1(d) are image plots of loadings,
A(1), for settings 1, 2, 4 and 5.
Figure 4.1: Loadings A(1) for settings 1, 2, 4 and 5.
Setting 1: All groups contribute to correlation between X(1) and X(2). In this scenario, we
let all 10 groups in X(1) and X(2) contribute to the association between X(1) and X(2). We
generate the first 100 entries of A(1) ∈ <r×100 and A(2) ∈ <r×100 for each r as independent
and identically distributed (i.i.d.) random samples from the uniform distribution on the
set [−0.5,−0.3] ∪ [0.3, 0.5], but for the 10 main variables, we multiply the effect size by 2.
The remaining p1−100 entries in A(1) for each r is set to 0. Similarly for A(1). The entries
in Un×r are randomly generated from N(0, 1). The data matrices X(1), X(2), and y are
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generated, respectively, as
X(1) = UA(1) +E(1), X(2) = UA(2) +E(2), y = Ua+ e
Here, we set r = 4, so U represents observation from four latent components. We set
a = [1 1 0 0] so that the response is only related to the first two shared components. The
entries in E1, E2, and e are all generated as i.i.d random samples from N(0, 1).
Setting 2: First three groups in A(1) and A(2) contribute to correlation between X(1),X(2).
In this scenario, we consider the situation where only some networks contribute to the
association between the two data types. We let the first 3 groups in A(1) and A(2), corre-
sponding to the first 30 variables in X(1) and X(2), contribute to the association between
X(1) and X(2). The entries in A(1) ∈ <r×30 and A(2) ∈ <r×30 are generated following
Setting 1.
Setting 3: Some variables within the groups contribute to correlation between X(1),X(2).
This scenario follows that of Setting 1 but we let only some variables within each of the 10
groups to contribute to the association between X(1) and X(2). We generate the entries
of A(1) ∈ <r×100 and A(2) ∈ <r×100 following Setting 1 but we randomly set at most 5
coefficients within each group to zero.
Setting 4: Some variables and some groups in A(1) and A(2) contribute to correlation be-
tween X(1),X(2). This Setting follows Setting 2 but we let only some variables within the
first three groups contribute to the association between X(1) and X(2). We generate the
entries of A(1) ∈ <r×30 and A(2) ∈ <r×30 following Scenario 1 but we randomly set at most
5 coefficients within each group to zero.
Setting 5: None overlapping components and all 100 variables contribute to correlation be-
tween X(1) and X(2). In Settings 1-4, we considered situations where latent components
overlapped with respect to the significant variables. In this Setting, we consider none over-
lapping components. Specifically, data are generated according to Setting 1, but the first
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25 signal variables are loaded on component 1, the next 25 variables on component 2, and
so on. The last 25 signal variables are loaded on component 4. Similar to Setting 1, there
are 10 groups or networks comprising of the 100 signal variables. This Setting tests our
methods ability to identify all 4 components, all 10 groups, and all 100 important variables.
4.1.1 Competing Methods
We compare the performance of our methods with association only and joint association
and prediction methods. For the association only-based methods, we consider the sparse
CCA [ SELPCCA] (Safo et al. (2018)) and Fused sparse CCA [FusedCCA] (Safo et al.
(2018)) methods. FusedCCA incorporates prior structural information in sparse CCA by
allowing variables that are connected to be selected or neglected together. We perform
FusedCCA and SELPCCA using the Matlab code the authors provide. For FusedCCA, we
assume that variables within each group are all connected since the method takes as input
the connections between variables. For the joint association and prediction methods, we
consider the CCA regression (CCAReg) method by Luo et al. (2016). We implement CCA
regression using the R package CVR . Once all the canonical variates are extracted, they
are used to fit a predictive model for the response y, and then to compute test MSE.
4.1.2 Evaluation Criteria
To evaluate the effectiveness of the methods, we fit the models using the training data
and then compare different methods based on their performance in feature selection and
prediction on an independently generated test data of the same size. To evaluate feature
selection, we use the number of predictors in the true active set that are not selected (false
negatives), the number of noise predictors that are selected (false positives), and F-score
(harmonic mean). To evaluate prediction, we use the mean square error obtained from the
testing set. We use 20 Monte Carlo datasets and report averages and standard errors.
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4.1.3 Simulation results
In Table 4.2, we report averages of the evaluation measures for Scenario One. We first
compare our method with incorporation of network information (BIPNet) and without
using the network information (BIP). In Settings 1-4, both methods identify one component
as important and related to the response. This is not surprising since all 100 important
variables on each component overlap in this setting, resulting in our method identifying
only one of these components. In Setting 5 where important variables did not overlap on the
four latent components, the proposed methods identify at least two components 13 times
out of 20 simulated data sets. We note that in general, conmpared to BIP, BIPNet has
lower false negatives, lower positive rates, competitive or higher harmonic means, and lower
MSEs. These results demonstrate the benefit of incorporating group information in feature
selection and prediction. We observe a sub-optimal performance for both BIPNet and BIP
in Settings 4 and 5, more so in Setting 5 where important variables do not overlap on the
latent components. We also assess the group selection performance of BIPnet as follows.
We compute AUC by using marginal posterior probabilities of group membership rlk’s.
Table 4.1 shows that most of groups in settings 1, 2 and 5 had been identified correctly.
However, the method had difficulties selecting groups in cases where only a few number of
features contribute to the association between data types (settings 3 and 4).
We next compare the proposed methods to the other existing methods. For the other
methods, we estimate both the first and the first four canonical variates. We report the
results from the first canonical variates here, and the results for the first four canonical
covariates in the online supplementary material, Section 8. For feature selection, a variable
is deemed selected if it has at least one nonzero coefficient in any of the four estimated
components. We observed that for SELPCCA, CCAReg, and FusedCCA in general, the
first canonical variates from each data type result in lower false negatives, lower false
positives, higher harmonic means, and competitive MSE for Settings 1-4 compared to
results from the first four canonical variates (see web supplementary materials, Section
8). In Setting 5 where signal variables do not overlap on the four true latent components,
we expect the first four canonical variates to have better feature selection and prediction
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results, and that is what we observe in Table 4.2. Across Settings 1-4, BIP and BIPNet
had lower false negatives, lower or comparable false positives, higher harmonic means, and
competitive MSEs when compared to two step methods: association followed by prediction.
The feature selection performance of the proposed methods was also better when compared
to CCAReg, a joint association and prediction method. CCAReg had lower MSEs in general
when compared to the proposed and the other methods. BIPNet and BIP had higher false
negatives in Setting 5 compared to Settings 1-4, nevertheless lower than CCAReg and
SELPCCA.
These simulation results suggest that incorporating group information in joint associ-
ation and prediction methods result in better performance. Although the performance of
the proposed methods are superior than existing methods in most Settings, our findings
suggest that the proposed methods tend to be better at selecting most of the true signals
in the settings where latent components overlap with regards to important variables. In
non overlapping settings, our methods tend to select some of the true signals (resulting in
higher false negatives). However, the proposed methods tend to have lower false positives,
which suggest that we are better at not selecting noise variables. This feature is especially
appealing for high-dimensional data problems where there tend to be more noise variables.
4.2 Scenario Two: None of the component is shared across data
types
We consider the scenario where there is no shared component across the two data types.
This scenario is similar to standard factor analysis or principal component analysis for each
data type independently, and accounts only for the individual variations explained by each
data type. The entries in U are generated from N(0, 1). The data matrices are generated,
respectively, as
X(1) = U1,2A
(1)
1,2 +E
(1), X(2) = U3,4A
(2)
3,4 +E
(2), y = Ua+ e.
Here, r = 4, U1,2 = (u1,u2) is a matrix of the first two latent components in U . Similarly
for U3,4. We consider two cases, overlapping and none overlapping components. In the
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overlapping case, the true sparse loading matrix A
(1)
1,2 has 100 signal variables loaded on
the first two components; there are fifty variables on each component. This is also true
for A
(2)
3,4. In the none overlapping case, the 100 signal variables in A
(1)
1,2 (similarly A
(1)
3,4) do
not overlap; there are 50 variables in each component. We set a = [1 0 1 0] so that the
response is only related to the first and third components. The entries in E1, E2, and e
are all generated as i.i.d random samples from N(0, 1).
4.2.1 Results
Table 4.3 shows the averages of the evaluation measures for Scenario Two. As before, we
estimate both the first and the first four canonical variates for the other methods, and report
results using subscripts 1 and 4 respectively. From Table 4.3, compared to SELPCCA, an
association only method that does not utilize prior information, BIPNet and BIP have
lower false negatives, lower false positives, higher harmonic means, and lower MSEs in the
overlapping case. This findings hold true, generally, when compared to FusedCCA, an
association only method that considers variable-variable interactions in sparse CCA. The
proposed methods also yield better results in both feature selection and prediction when
compared to CCAReg, a joint association and prediction method. The results in the non
overlapping case in this Scenario are consistent with results from Setting 5 in Scenario One.
For the overlapping case, our methods were able to identify the first (i.e., A
(1)
1,2) and last
two (i.e., A
(2)
3,4) components 17 and 18 times respectively out of 20 simulated data sets (i.e
85% and 90%). For the none overlapping case, it was respectively 75%, 65%, 85% and 65%
for components 1, 2, 3 and 4.
4.3 Scenario Three: Some shared components and individual
variations
We consider the scenario where some components are shared across the two data types,
and there are both shared and individual components predicting the outcome. As before,
the entries in U are generated from N(0, 1). The data matrices are generated, respectively,
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as
X(1) = U1,2A
(1)
1,2 +U3A
(1)
3 +E
(1), X(2) = U1,2A
(2)
1,2 +U4A
(2)
4 +E
(2), y = Ua+ e.
Here, r = 4, U = (u1,u2,u3,u4), U1,2 = (u1,u2) is a matrix of the first two latent
components in U that are shared across the two data types. U3 = (u3) is a vector of
the third latent component in U that is unique to data type X(1). Similarly, U4 = (u4)
is unique to data type X(2). We consider two cases, overlapping shared components and
none overlapping components. In the overlapping case, the true sparse loading matrices
A(1) have 50 signal variables (corresponding to the first 50 variables) loaded on the first
two components (denoted by A
(1)
1,2), 50 signal variables on the third component (A
(1)
3 ), and
no signal variable on the fourth component. This is also true for A(2) but there are 50
signal variables loaded on the fourth component (A
(2)
4 ) and no signal variables on the third
component. In the none overlapping case, the 50 signal variables inA
(1)
1,2 do not overlap; the
first 25 variables in the first component are important, and variables 26 to 50 are important
in the second component. We set a = [1 0 1 1] so that the response is only related to the
first latent component that is shared, and the individual latent components that is unique
to the data types. The entries in E1, E2, and e are all generated as i.i.d random samples
from N(0, 1).
4.3.1 Results
This scenario tests the proposed methods ability to identify both shared and individual
components, as well as important variables that are loaded on these components. Table
4.4 shows the averages of the evaluation measures for Scenario Three. As before, we report
the first and the first four canonical variates using subscripts 1 and 4 respectively. Similar
to Setting 5 in Scenario One, the results from the first four canonical variates are generally
better than that from the first canonical variates. We compare our methods to these results.
From Table 4.4, we observe that the proposed methods have lower false negatives, lower
positives, and higher harmonic means compared to the other methods. The prediction
performances for the proposed methods are sub-optimal. Consistent with results from the
other Scenarios, the proposed methods have higher false negatives in the none overlapping
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case, nevertheless better than CCAReg and SELPCCA. Meanwhile, the false positives are
consistent in both overlapping and non overlapping cases, which again indicate that the
methods are able to ignore the noise variables while selecting some of the true signals.
In the overlapping case, our methods were able to detect components 1 and 2 for all the
20 simulated data sets. Moreover, components 3 and 4 were identified 15 and 10 times
respectively. On the other hand, for the none overlapping case, components 1, 2, 3 and 4
were identified 75%, 25%, 25%, and 25% respectively. These findings, together with that
from Scenarios One and Three, underscore the benefit of considering group information in
joint association and prediction methods.
Table 4.1: AUCs for group selection performance in scenario 1
Setting 1 Setting 2 Setting 3 Setting 4 Setting 5
Data type 1 1 (0) 0.86 (0.04) 0.58 (0.03) 0.64 (0.06) 1 (0)
Data type 2 1 (0) 0.81 (0.05) 0.56 (0.03) 0.62 (0.06) 1 (0)
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Table 4.2: Simulation results for Scenario One: variable selection and prediction perfor-
mances. FNR1; false negative rate for X1. Similar for FNR2. FPR1; false positive rate
for X1. Similar for FPR2; F11 is F-measure for X1. Similar for F12; MSE is mean square
error.
Method Setting. FNR1 FNR2 FPR1 FPR2 F11 F12 MSE
BIPnet S1 0 (0) 0 (0) 0.02 (0.02) 0 (0) 100 (0.00) 100 (0) 2.09 (0.04)
BIP S1 0 (0) 0 (0) 0.14 (0.06) 0.16 (0.04) 99.73 (0.12) 99.68 (0.08) 2.16 (0.04)
SELPCCA S1 0 (0) 0 (0) 0.4 (.09) 0.5 (.12) 99.21 (0.17) 99.02 (0.23) 2.11 (0.04)
CCAReg S1 90.25(1.73) 90.40 (1.87) 1.81 (3.32) 1.71 (3.35) 15.34 (1.87) 14.98 (2.01) 2.01 (0.05)
FusedCCA S1 0.00 (0.00) 0.00 (0.00) 7.88 (0.76) 10.40 (0.78) 86.69 (1.17) 83.05 (1.08) 2.14 (0.04)
BIPnet S2 0 (0) 0 (0) 0.21 (0.15) 0.22 (0.21) 98.57 (0.98) 98.67 (1.25) 2.15 (0.05)
BIP S2 0 (0) 0 (0) 0.61 (0.28) 0.45 (0.19) 96.14 (1.71) 96.98 (1.3) 2.2 (0.05)
SELPCCA S2 22.00 (8.75) 16.33 (7.51) .02 (.01) .04 (.02) 80.17 (7.81) 85.91 (6.37) 2.13 (0.04)
CCAReg S2 85.83 (1.87) 86.00 (1.79) 1.54 (.63) 1.27 (.47) 19.52 (1.77) 19.76 (1.47) 2.03 (0.04)
FusedCCA S2 0.00 (0.00) 0.00 (0.00) 17.14 (0.33) 17.13 (0.39) 42.79 (0.47) 42.83 (0.53) 2.21 (0.04)
BIPnet S3 0 (0) 0 (0) 0.89 (0.11) 1.24 (0.12) 96.88 (0.39) 95.69 (0.41) 2.08 (0.04)
BIP S3 0 (0) 0 (0) 0.88 (0.14) 0.73 (0.11) 96.93 (0.47) 97.43 (0.4) 2.1 (0.05)
SELPCCA S3 8.50 (5.86) 8.42 (5.81) 0.16 (.06) .14 (.05) 92.02 (5.07) 92.20 (5.04) 2.05 (0.04)
CCAReg S3 83.00 (2.50) 82.92 (2.60) 2.42 (.68) 2.51 (.74) 23.21 (2.71) 23.02 (2.87) 1.98 (0.04)
FusedCCA S3 0.00 (0.00) 0.00 (0.00) 12.70 (3.01) 13.89 (3.23) 71.51 (2.31) 69.80 (2.43) 2.18 (0.04)
BIPnet S4 0 (0) 0 (0) 2.81 (0.28) 3.07 (0.34) 74.73 (1.9) 73.34 (2.26) 2.24 (0.05)
BIP S4 0 (0) 0 (0) 1.82 (0.34) 1.99 (0.36) 83.12 (2.82) 81.91 (2.92) 2.27 (0.04)
SELPCCA S4 51.32 (9.50) 42.89 (9.42) 0.10 (0.10) 0.00 (0.0) 54.36 (8.08) 63.42 (8.15) 2.16 (0.04)
CCAReg S4 77.63 (1.87) 78.68 (1.85) 3.12 (0.68) 2.71 (0.67) 22.80 (1.15) 23.49 (1.43) 2.01 (0.05)
FusedCCA S4 0.00 (0.00) 0.00 (0.00) 19.51 (2.22) 19.64 (2.53) 30.39 (1.03) 30.55 (1.07) 2.58 (0.06)
BIPnet S5 61.05 (2.82) 59.75 (3.12) 0.05 (0.03) 0 (0) 54.91 (2.78) 56.12 (3.03) 2.35 (0.21)
BIP S5 63 (2.65) 60.35 (2.48) 0.04 (0.03) 0.06 (0.03) 52.89 (2.9) 55.79 (2.63) 2.64 (0.22)
SELPCCA S5 93.40(1.55) 93.30(1.85) 0.06(0.06) 0.00 (0.00) 11.60 (2.52) 11.57 (3.00) 2.72 (0.13)
CCAReg S5 88.85 (1.81) 87.95 (1.89) 1.44 (0.52) 1.40(0.50) 19.83 (2.30) 21.51 (2.44) 2.26 (.14)
FusedCCA S5 0.00 (0.00) 0.00 (0.00) 3.47 (0.81) 2.31 (0.55) 93.89 (1.37) 95.77 (0.97) 2.72 (0.11)
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Table 4.3: Simulation results for Scenario Two: variable selection and prediction perfor-
mances. Subscripts 1 and 4 respectively denote results from the first and the first four
canonical variates. FNR1; false negative rate for X1. Similar for FNR2. FPR1; false
positive rate for X1. Similar for FPR2; F11 is F-measure for X1. Similar for F12; MSE is
mean square error.
Method FNR1 FNR2 FPR1 FPR2 F11 F12 MSE
Overlap
BIPnet 0 (0) 0.05 (0.05) 0.05 (0.03) 0.04 (0.02) 99.90 (0.07) 99.90 (0.05) 2.12(0.04)
BIP 0 (0) 1.25 (0.84) 0.21 (0.06) 0.15 (0.05) 99.58 (0.13) 99.04 (0.44) 2.16 (0.06)
CCAReg1 71.80 (5.56) 75.55 (5.04) 8.81 (2.85) 11.40 (3.32) 29.28 (3.57) 25.05 (3.06) 2.19 (0.04)
CCAReg4 74.85 (2.63) 74.05 (2.65) 10.20 (1.77) 9.78 (1.68) 28.98 (1.77) 30.04 (1.85) 2.32(0.06)
SELPCCA1 68.75(7.23) 93.45 (1.71) 0.64 (0.42) 1.69(0.42) 39.71 (7.21) 13.81 (2.76) 2.37 (0.05)
SELPCCA4 62.70(2.86) 56.45 (3.42) 4.71 (0.39) 4.26(0.47) 46.65 (3.10) 52.64 (3.83) 2.23(0.04)
FusedCCA1 0.00 (0.00) 0.00 (0.00) 6.30 (3.21) 10.19 (3.92) 92.18 (3.21) 87.30 (3.61) 2.24 (0.07)
FusedCCA4 0.00 (0.00) 0.00 (0.00) 33.06 (4.80) 41.81 (4.36) 64.40 (3.93) 57.00 (2.89) 2.18 (0.04)
No Overlap
BIPnet 29.85 (6.02) 43.85 (5.66) 0.01 (0.01) 0.02 (0.02) 79.48 (4.41) 68.76 (4.58) 2.00(0.09)
BIP 34.2 (8.3) 50.35 (8.58) 0.11 (0.05) 0.22 (0.07) 72.38 (7.13) 57.57 (7.6) 2.16 (0.06)
CCAReg1 78.65 (3.91) 76.80 (4.29) 6.96 (2.44) 6.31 (2.40) 25.41 (2.72) 27.58 (3.01) 2.27 (0.08)
CCAReg4 69.20 (2.70) 67.95 (2.79) 8.25 (1.72) 8.33 (1.66) 36.79 (1.41) 37.85 (1.42) 1.77(0.04)
SELPCCA1 87.35(1.48) 87.90 (1.89) 0.36 (0.16) 0.31(0.09) 21.59 (2.31) 20.46 (2.80) 2.44 (0.07)
SELPCCA4 59.35(2.81) 57.55 (1.69) 4.51 (1.84) 3.10(1.02) 51.08 (2.49) 55.28 (2.32) 2.02(0.07)
FusedCCA1 0.00 (0.00) 0.00 (0.00) 1.45 (0.65) 5.53 (1.63) 97.44 (1.08) 91.35 (2.35) 2.23 (0.07)
FusedCCA4 0.00 (0.00) 0.00 (0.00) 25.26 (3.44) 30.21 (4.70) 69.11 (3.16) 66.53 (3.88) 1.84 (0.04)
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Table 4.4: Simulation results for Scenario Three: variable selection and prediction perfor-
mances. Subscripts 1 and 4 respectively denote results from the first and the first four
canonical variates. FNR1; false negative rate for X1. Similar for FNR2. FPR1; false
positive rate for X1. Similar for FPR2; F11 is F-measure for X1. Similar for F12; MSE is
mean square error.
Method FNR1 FNR2 FPR1 FPR2 F11 F12 MSE
Overlap
BIPnet 30.2 (4.7) 23.25 (5.22) 0.01 (0.01) 0.05 (0.02) 80.52 (3.18) 84.78 (3.49) 2.90 (0.14)
BIP 31.55 (4.73) 14.5 (5.02) 0.12 (0.04) 0.11 (0.05) 79.34 (3.14) 90.2 (3.41) 3.26 (0.5)
CCAReg1 82.30( 2.57) 82.10 (2.95) 4.50 (1.29) 4.25 (1.35) 24.23 (2.52) 24.45 (2.69) 3.11 (0.05)
CCAReg4 72.60( 2.66) 74.60 (2.10) 9.38 (1.98) 9.40 (2.13) 32.13 (1.49) 30.74 (1.24) 2.38 (0.05)
SELPCCA1 83.55(4.42) 93.05 (2.28) 0.01 (0.01) 0(0) 24.18 (5.61) 11.82 (2.92) 3.26 (0.05)
SELPCCA4 61.65(3.67) 63.00 (2.07) 5.05 (1.94) 2.43(0.34) 47.73 (1.96) 50.07 (2.56) 2.52 (0.07)
FusedCCA1 0.00 (0.00) 0.00 (0.00) 5.15 (0.55) 7.00 (0.69) 90.83 (0.89) 87.96 (1.04) 3.19 (0.06)
FusedCCA4 0.00 (0.00) 0.00 (0.00) 32.28 (3.54) 24.59 (3.62) 64.00 (3.01) 69.97 (3.22) 2.37 (0.04)
No Overlap
BIPnet 51.75 (4.76) 43.85 (6.06) 0.04 (0.02) 0.05 (0.03) 62.28 (4.52) 67.9 (5.33) 3.42 (0.48)
BIP 56.7 (5.76) 41.05 (5.67) 0.1 (0.03) 0.14 (0.05) 56.14 (5.4) 70.46 (5.07) 3.26 (0.5)
CCAReg1 88.60( 7.92) 87.10 (2.24) 2.67 (0.62) 2.00 (0.52) 17.38 (2.68) 19.72 (2.99) 3.00 (0.09)
CCAReg4 76.80( 2.61) 73.60 (2.92) 7.90 (1.79) 7.49 (1.93) 28.88 (1.23) 32.62 (1.37) 2.06 (0.06)
SELPCCA1 94.85(1.64) 92.15 (2.09) 0.40 (0.40) 0.01(0.01) 8.57 (2.22) 13.30 (3.36) 3.46 (0.08)
SELPCCA4 67.90(2.39) 64.55 (1.73) 2.60 (1.25) 0.98(0.23) 44.53 (1.81) 50.49 (1.98) 2.35 (0.05)
FusedCCA1 0.00 (0.00) 0.00 (0.00) 6.10 (1.66) 5.11 (1.11) 90.35 (2.21) 91.37 (1.71) 3.18 (0.08)
FusedCCA4 0.00 (0.00) 0.00 (0.00) 32.13 (4.47) 24.84 (5.27) 64.33 (3.44) 72.40 (4.36) 2.50 (0.07)
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5 Application to atherosclerosis disease
We apply the proposed methods to analyze gene expression, genetics, and clinical data
from the PHI study. The main goals of our analyses are to: 1) identify genetic variants,
genes, and gene pathways that are potentially predictive of 10-year atherosclerosis disease
(ASCVD), and 2) illustrate the use of the shared components or scores in discriminating
subject at high- vs low-risk for developing ASCVD in 10 years.
There were 340 patients with gene expression and SNP data, as well as clinical covariates
to calculate their ASCVD score. The following clinical covariates were added as a third
data set: age, gender, BMI, systolic blood pressure, low-density lipoprotein (LDL), and
triglycerides. The gene expression and SNP data were each standardized to have mean zero
and standard deviation one for each feature. Details for data preprocessing are provided
in web supplementary material Section 10.1.
To obtain the group structure of genes, we performed a network analysis using Ingenuity
Pathway Analysis (IPA), a software program which can analyze the gene expression patterns
using a build-in scientific literature based database (according to IPA Ingenuity Web Site,
www.ingenuity.com). By mapping our set of genes with the IPA gene set, we identified
p1 = 561 genes within K1 = 25 gene networks. To obtain the group structure of SNPs
(p2 = 413 SNPs), we identified genes nearby SNPs on the genome using the R package
bioMart. We found in total K2 = 31 genes that will represent groups for the SNP data.
The list of those groups for both data types are shown in the web supplementary material,
Section 9.
We divided each of the data type into training (n = 272) and testing (n = 68), ran
the analyses on the training data to estimate the latent scores (shared components) and
loading matrices for each data, and predicted the test outcome using the testing data. For
the other methods, the training data were used to identify the optimal tuning parameters
and to estimate the loading matrices. We then computed the training and test scores using
the combined scores from both the gene expression and SNP data. We fit a linear regression
model using the scores from the training data, predicted the test outcome using the test
scores, and computed test MSE.
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To reduce the variability in our findings due to the random split of the data, we also
obtained twenty random splits, repeated the above process, and computed average test
MSE and variables selected. We further attempted to assess the stability of the variables
selected by considering variables that were selected at least 12 times (60% ) out of the
twenty random splits.
Prediction error and genes and genetic variants selected : For the purpose of
illustrating the benefit of including covariates, we also considered these additional models:
i) our BIPnet model, using both molecular data and clinical data (age, gender, Body mass
index, Systolic blood pressure, low-density lipoprotein (LDL), triglycerides) [BIPnet+Cov],
(ii) our BIP model, using both clinical and molecular data (BIP+ Cov), and iii) sparse PCA
on stacked omics and clinical data (SPCA + Cov). For the sparse PCA, we used the method
of Witten et al. (2009) with l1-norm regularization. We were not able to incorporate clinical
data in the integrative analysis methods under comparison since they are applicable to two
datasets. Figure 5.1 shows marginal posterior probabilities (MPP) of the 4 components
for each datatype (SNPs, mRNA and response) for one random split of the data. It
shows that for each of the 4 methods, only one component is active (i.e MPP> 0.5) for
gene expression, and two components for SNP data. None of the component is active for
the response variable when applied to methods without clinical data (BIPnet and BIP).
However, when applied to methods that incorporate covariates (BiPnet+Cov, BIP+Cov),
we can obviously identify at least one active component for the response variable. This
result shows the importance of incorporating clinical data in our approach.
Table 5.1 gives the average test mean square error and numbers of genes and genetic
variants identified by the methods for twenty random split of the data. For FusedCCA, we
assumed that all genes within a group are connected (similarly for SNPs). We computed
the first and the first four canonical variates for FusedCCA, SELPCCA, and CCAReg
using the training dataset, and predicted the test ASCVD score using the combined scores
from both the gene expression and SNP data. BPINet+ Cov and BIP + Cov have better
prediction performances (lower MSEs) when compared to BIPNet, BIP, and the other
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methods. We observe from that BIPNet and BIPNet + Cov tend to be more stable than
BIP and BIP + Cov (125 genes and 55 SNPs vs 0 genes and 54 SNPs selected at least 12
times). Together, these findings demonstrate the merit in combining molecular data, prior
biological knowledge, and clinical covariates in integrative analysis and prediction methods.
We further assessed the biological implications of the groups of genes and SNPs identi-
fied by the proposed methods. We selected (MPP>0.5) in total 125 genes and 55 SNPs at
least 12 times out of the 20 random splits for both BIPNet and BIPNet + Cov (see Figures
10.1 and 10.2 in supplementary material for a random split). Networks 1 and 10 (refer
to web supplementary material Table 9.2 for group description) were identified 18 times
(90%) out of the 20 random splits of the data. Cell-To-Cell signaling and interaction that
characterizes network 10 has led to novel therapeutic strategies in cardiovascular diseases
(Shaw et al., 2012). Genes PSMB10 and UQCRQ, and SNPs rs1050152 and rs2631367
were the two top selected genes (highest averaged MPPs) and SNPs respectively across
the 20 random splits. The gene PSMB10, a member of the ubiquitin-proteasome system,
is a coding gene that encodes the Proteasome subunit beta type-10 protein in humans.
PSMB10 is reported to play an essential role in maintaining cardiac protein homeostasis
(Li et al., 2018) with a compromised proteasome likely contributing to the pathogenesis
of cardiovascular diseases (Wang and Hill, 2015). The SNPs rs1050152 and rs2631367
found in genes SLC22A4 and SLC22A5, belong to the gene family SLC22A which has been
implicated in cardiovascular diseases. Other genes and SNPs with MPP> .85, on average,
are reported in the web supplementary material in Tables 9.1 and 9.3. These could be
explored for their potential roles in cardiovascular (including atherosclerosis) disease risk.
Discriminating between high- vs low-risk ASCVD using the shared compo-
nents: We illustrate the use of the shared components or scores in discriminating subjects
at high- vs low-risk for developing ASCVD in years. For this purpose, we dichotomized
the response into two categories: low-risk and high-risk patients. ASCVD score less or
equal to the median ASCVD was considered low-risk, and ASCVD score above the median
ASCVD was considered high-risk. We computed the AUC for response classification using
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a simple logistic regression model with the most significant (i.e. the highest MPP for our
method) component associated with the response as covariates. For the other methods, the
AUC was calculated using the first canonical correlation variates from the combined scores.
Figure 5.2 shows that the components selected by our methods applied to the omics and
clinical data are able to discriminate clearly the two risk groups compared to our methods
applied to the omics data only. The estimated AUCs for the omics plus clinical covariates
are much higher than those obtained from omics only applications (e.g AUC is 1.00 for
the training set and AUC is 0.94 for the test set using BIPnet+Cov). When compared to
the two-step methods CCAReg and SELPCCA, the estimated AUCs from our methods are
considerably higher than the AUC’s from these methods. These findings demonstrate the
importance of one-step methods like we propose here, and also the merit in incorporating
both clinical and molecular data in integrative analysis and prediction models.
Figure 5.1: MPPs of the 4 component indicators, γ
(m)
l , l = 1, 2, 3, 4, and m =Response (i.e.
ASCVD scores), Genes, SNPs and covariates, with respect to our four proposed methods.
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Table 5.1: Average test mean squared error and number of variables selected by the methods
for twenty random split of the data. Genes/SNPs selected ≥ 12 are genes or snps selected
at least 12 times out of twenty random splits. Subscripts 1 and 4 respectively denote results
from the first and the first four canonical variates. MSE is mean square error.
Method MSE Average Average Genes selected SNPs selected
# Genes # SNPs ≥ 12 times ≥ 12 times
BIPnet 1.362 (0.033) 128.35 113.65 125 55
BIPnet + Cov 0.758 (0.125) 122 95.8 125 55
BIP 1.363 (0.032) 68.7 88.8 0 54
BIP + Cov 0.766 (0.153) 54.7 82.5 0 54
SPCA1 + Cov 1.367 (0.035) 0 5.55 0 0
SPCA4 + Cov 1.382 (0.036) 23.95 132.60 0 113
SELPCCA1 1.373 (0.035) 52.35 30.35 1 23
SELPCCA4 1.377 (0.036) 310.650 170.60 174 102
CCAReg1 1.371(0.008) 48.85 43.55 0 0
CCAReg4 1.382 (0.034) 11.30 12.85 0 0
FusedCCA1 1.370 (0.032) 560.2 402.40 561 398
FusedCCA4 1.379 (0.034) 561 418.05 561 421
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Figure 5.2: Estimated latent U scores on both training and test sets for low and high CVD
risks with respect to our methods.
Figure 5.3: Estimated latent U scores on both training and test sets for low and high CVD
risks with respect to competing methods.
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6 Conclusion
We have presented a Bayesian hierarchical modeling framework that integrates in a unified
procedure multi-omics data, a response variable, and clinical covariates. We also extended
the methods to integrate grouping information of features through prior distributions. The
numerical experiments described in this manuscript show that our approach outperforms
competing methods mostly in terms of variable selection performance. The data analysis
demonstrated the merit of integrating omics, clinical covariates, and prior biological knowl-
edge, while simultaneously predicting a clinical outcome. The identification of important
genes or SNPs and their corresponding important groups ease the biological interpretation
of our findings.
Several extensions of our model are worth investigating. First, using latent variable
formulations, we can naturally extend our approach to other types of response variables
such as survival time, binary or multinomial responses or mixed response outcomes (e.g.
both continuous and binary). Second, the proposed method is only applicable to complete
data and do not allow for missing values. A future project could extend the current methods
to the scenario where data are missing using Bayesian imputation methods or the approach
proposed by Chekouo et al. (2017) for missing blocks of data.
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Supplemental Material
In the online Supplemental Materials, we provide details to sample our parameters, and
present more results from simulated data, in particular, sensitivity analysis results. We
provide a detailed description of the groups from each of the data types (SNPs and gene
expression). We have created an R package called BIPnet (GNU zipped tar file) for im-
plementing the methods. Its source R and C codes, along with the user pdf manual are
submitted with this manuscript. The package also contains functions used to generate
simulated data. Data used for the analyses may be requested from the Emory Predictive
Health Institute.
Supplementary materials for “Bayesian Integrative Anal-
ysis and Prediction with Application to Atherosclerosis
Cardiovascular Disease”
7 Posterior inference
We present below the conditional distributions used to update the parameters.
7.1 Sampling γ
(m)
l and η
(m)
lj
Equation (1) in the main paper can also be written as x
(m)
·j = U(γ)a
(m)
·j(η) +e
(m)
·j , j = 1, ..., pm,
where a
(m)
·j(η) is the j-column vector of A
(m) with η
(m)
lj = 1, and U(γ) is a sub-matrix of U
with columns l’s verifying γ
(m)
l = 1. After integrating a
(m)
·j(η), we have
p(x
(m)
·j |γ(m),U(γ),η(m)·j , σ2(m)j , τj) = MVN(x·j,0, σ2(m)j Σj)
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where Σj = U(γ)D(τj)U
T
(γ) + In. In what follows, we removed the superscript “
(m)” to
simplify formulas. We have then,
p(γ,N |X,U ,σ, τ ) ∝
p∏
j=1
p(x·j|γ,U(γ),η·j , σ2j , τj)p(η·j|γ)p(γ)
∝
p∏
j=1
MVN(x·j,0, σ2jΣj)
r∏
l=1
p(ηlj|γl)p(γl)
=
p∏
j=1
Gj(γ,η·j)
r∏
l=1
p(γl), (7)
where N = (ηlj) and Gj(γ,η·j) = MVN(x·j,0, σ2jΣj)
∏r
l=1 p(ηlj|γl). To sample (γ,N )
from equation (7), we adopt a Metropolis Hasting step. The proposal distribution will be
defined as
Q(γ′l,η
′
l·|γl,η·l) = γlδ0(γ′l)δ0(η′l·) + (1− γl)δ1(γ′l)p(η′l·|X,U , γ′l = 1) (8)
where
p(η′l·|X,U , γ′l = 1) =
p∏
j=1
P
η′lj
lj (1− Plj)1−η
′
lj , Plj =
Gj(γ
1,η1·j)
Gj(γ1,η1·j) +Gj(γ1,η
0
·j)
,
γ1 = (γ1, ..., γl = 1, ...γr), η
1
·j = (η1j, ..., ηlj = 1, ..., ηrj) and η
0
·j = (η1j, ..., ηlj = 0, ..., ηrj).
From proposal (8), if the current component is not active, that is, γl = 0, we propose
to activate this group by setting γ′l = 1, and sample from the conditional distribution,
p(η′l·|X,U , γ′l = 1), of the indicators for variable selection ηl·. We then determine whether
to accept this proposal or not by the Metropolis-Hastings acceptance-rejection rule. Con-
versely, if the current component is active, that is, γl = 1, we propose to make it inactive
by setting γ′l = 0 and setting all the indicators η
′
l· within this component to zero. Again, we
determine whether to accept this proposal or not by the acceptance-rejection rule. When
m = 0, we will always assume ηl1 = 1 and only γ
0
l is updated.
7.2 Sampling σ
2(m)
j , τ
2(m)
lj and λ
2(m)
lj
We remove the superscript (m) to simplify the notations. We easily show that the full
conditional distributions of σ2j ’s are obtained as
p(σ2j |·) = IG(σ2j ; a0 +
n
2
,
1
2
xT·jΣ
−1
j x·j + b0).
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Also, when ηlj = 1, the full conditional distributions of τ
2
lj and λ
2
lj are respectively the
inverse of inverse Gaussian distribution and a gamma distribution. More specifically,
1
τ 2lj
|· ∼ InverseGaussian(µ′, λ′2)
and λ2lj|· ∼ Γ(α + 1, bl0 + P Tj bl + τ 2lj)
where µ′ =
√
2λ2ljσ
2
j
A2lj
and λ′2 = 2λ2lj
Otherwise, we update them from these distributions (pseudo-priors)
τ 2lj|λ2lj ∼ Exp(λ2lj) and λ2lj|bl· ∼ Γ(α, bl0).
7.3 Sampling A
Full conditional distributions of a
(m)
·j(η) are obtained as
p(a
(m)
·j(η)|..) = Normal(a(m)·j(η);µa,Σa)
where µa = ΣaU
T
(γ)x
(m)
·j , Σ
−1
a = σ
−2(m)
j (U
T
(γ)U(γ) + Inγ ) and nγ is the number of active
components for m. We also have a
(m)
lj = 0 if η
(m)
lj = 0.
7.4 Sampling U
Let denote p = p0 + pM+1
∑M
m=1
∑pm
j=1 η
(m)
lj , the total number of features included in the
model (including the outcome and the set of covariates). We can write also x
(m)
i· =
A(m)Tui· + e
(m)
i· , i = 1, ..., n and let xi· = (yi,x
(1)
i· , . . . ,x
(M)
i· ) be the p-vector of expres-
sion of sample i and A(η) = (A
(0),A
(1)
(η), . . . ,A
(M)
(η) ) be the r × p matrix of loads.
P (ui·|xi·,A(η)) ∝ P (xi·|ui·,A(η))P (ui·)
= exp{-1
2
[xi· −AT(η)ui·]TD(σ−2)[xi· −AT(η)ui·]} exp{-
1
2
uTi·ui·}
= exp{-1
2
[ui· − µi]TΣ−1ui [ui· − µi]}
where σ is the vector (σ(0),σ(1), . . . ,σ(M)). Hence, ui· is a multivariate normal distribution
with mean µui = ΣuiA(η)D(σ
−2)xi· and covariance matrix Σui = (A(η)D(σ
−2)AT(η) + Ir)
-1.
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7.5 Sampling (b
(m)
lk , r
(m)
lk ), l = 1, ..., r
P (blk, rlk|·) ∝
p∏
j=1
ηlj=1
P (λ2lj|bl)P (blk|rlk)P (rlk)
∝
pm∏
j=1
ηlj=1
(bl0 +
K∑
k=1
κjkrlkblk)
α exp{−κjkλljrlkblk} ×
× [(1− rlk)δ0 + rlk β
α0
0
Γ(α0)
bα0−1lk exp(−β0blk)]qrlkr (1− qr)1−rlk
where Pj = (κjk)K and κjk = 1 if j belongs to group k. We will sample (blk, rlk) using this
proposal (similar to Gottardo and Raftery (2008))
Q(b′lk, r
′
lk|blk, rlk) = rlkδ0(b′lk)δ0(r′lk) + (1− rlk)δ1(r′lk)Γ(b′lk;α?, β?)
where Γ(b′lk;α
?, β?) is the density of a gamma distribution with parameters α? and β? to
specify. From proposal (9), if the current pathway is selected in component l, i.e, rlk = 1, we
propose r′lk = 0 and b
′
lk = 0. Otherwise, if rlk = 0, we propose r
′
lk = 1 and b
′
lk ∼ Γ(α?, β?).
8 More simulation results
Table 8.1 shows complete simulation results of the competitive methods applied with both
2 and 4 shared components.
Table 8.1: Simulation results for Scenario One: variable selection and prediction perfor-
mances. Subscripts 1 and 4 respectively denote results from the first and the first four
canonical variates. FNR1; false negative rate for X1. Similar for FNR2. FPR1; false
positive rate for X1. Similar for FPR2; F11 is F-measure for X1. Similar for F12; MSE
is mean square error. FusedCCA4: method Fused CCA applied with 4 canonical variates.
FusedCCA1: method Fused CCA applied with one canonical variate
Method Setting FNR1 FNR2 FPR1 FPR2 F11 F12 MSE
BIPnet S1 0 (0) 0 (0) 0.02 (0.02) 0 (0) 99.95 (0.05) 100 (0) 2.09 (0.04)
BIP S1 0 (0) 0 (0) 0.2 (0.05) 0.12 (0.04) 99.6 (0.1) 99.75 (0.08) 2.16 (0.04)
SELPCCA1 S1 0 (0) 0 (0) 0.4 (.09) 0.5 (.12) 99.21 (0.17) 99.02 (0.23) 2.11 (0.04)
Continued on next page
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SELPCCA4 S1 31.35( 5.24) 26.60 (5.30) 13.00 (3.85) 12.38 (3.51) 63.28 (3.27) 67.07 (4.23) 2.09 (0.05)
CCAReg1 S1 90.25(1.73) 90.40 (1.87) 1.81 (3.32) 1.71 (3.35) 15.34 (1.87) 14.98 (2.01) 2.01 (0.05)
CCAReg4 S1 77.80 (4.32) 78.50 (4.51) 13.68 (3.32) 14.05 (03.35) 20.27 (3.05) 19.34 (2.74) 2.22 (0.05)
FusedCCA1 S1 0.00 (0.00) 0.00 (0.00) 7.88 (0.76) 10.40 (0.78) 86.69 (1.17) 83.05 (1.08) 2.14 (0.04)
FusedCCA4 S1 0.00 (0.00) 0.00 (0.00) 33.63 (4.11) 27.59 (3.16) 62.56 (3.06) 66.38 (2.55) 2.19 (0.04)
BIPnet S2 0 (0) 0 (0) 0.21 (0.15) 0.41 (0.28) 98.57 (0.98) 97.53 (1.66) 2.15 (0.05)
BIP S2 0 (0) 0 (0) 0.66 (0.26) 0.83 (0.36) 95.71 (1.68) 94.95 (2.1) 2.20 (0.05)
SELPCCA1 S2 22.00 (8.75) 16.33 (7.51) .02 (.01) .04 (.02) 80.17 (7.81) 85.91 (6.37) 2.13 (0.04)
SELPCCA4 S2 46.67 (4.04) 44.67 (3.75) 5.82 (0.42) 7.31 (1.38) 43.05 (3.15) 41.83 (2.15) 2.14 (0.04)
CCAReg1 S2 85.83 (1.87) 86.00 (1.79) 1.54 (.63) 1.27 (.47) 19.52 (1.77) 19.76 (1.47) 2.03 (0.04)
CCAReg4 S2 89.00 (1.53) 89.00 (1.30) 4.34 (1.65) 3.89 (1.50) 12.37 (0.62) 13.06 (0.73) 2.10 (0.04)
FusedCCA1 S2 0.00 (0.00) 0.00 (0.00) 17.14 (0.33) 17.13 (0.39) 42.79 (0.47) 42.83 (0.53) 2.21 (0.04)
FusedCCA4 S2 0.00 (0.00) 0.00 (0.00) 27.27 (1.22) 24.51 (1.30) 32.44 (0.97) 34.94 (1.06) 2.25 (0.04)
BIPnet S3 0 (0) 0 (0) 1.45 (0.15) 1.45 (0.13) 94.98 (0.48) 94.98 (0.44) 2.08 (0.04)
BIP S3 0 (0) 0 (0) 0.62 (0.15) 0.61 (0.12) 97.81 (0.52) 97.83 (0.43) 2.10 (0.05)
SELPCCA1 S3 8.50 (5.86) 8.42 (5.81) 0.16 (.06) .14 (.05) 92.02 (5.07) 92.20 (5.04) 2.05 (0.04)
SELPCCA4 S3 39.50 (2.95) 29.00 (2.09) 5.63 (0.28) 5.64 (0.45) 59.55 (2.12) 66.94 (1.65) 2.04 (0.04)
CCAReg1 S3 83.00 (2.50) 82.92 (2.60) 2.42 (.68) 2.51 (.74) 23.21 (2.71) 23.02 (2.87) 1.98 (0.04)
CCAReg4 S3 88.25 (1.97) 89.58 (1.93) 3.42 (1.30) 3.47 (1.33) 15.74 (1.80) 13.80 (1.4)6 2.02 (0.05)
FusedCCA1 S3 0.00 (0.00) 0.00 (0.00) 12.70 (3.01) 13.89 (3.23) 71.51 (2.31) 69.80 (2.43) 2.18 (0.04)
FusedCCA4 S3 0.00 (0.00) 0.00 0.00 25.47 2.31 29.16 3.59 53.62 2.34 51.52 2.74 2.22 (0.05)
BIPnet S4 0 (0) 0 (0) 2.61 (0.42) 2.62 (0.4) 77.37 (2.96) 77.09 (2.81) 2.24 (0.05)
BIP S4 0 (0) 0 (0) 2.58 (0.42) 3.14 (0.45) 77.68 (3.04) 74.04 (3.24) 2.27 (0.04)
SELPCCA1 S4 51.32 (9.50) 42.89 (9.42) 0.10 (0.10) 0.00 (0.0) 54.36 (8.08) 63.42 (8.15) 2.16 (0.04)
SELPCCA4 S4 36.58 (4.97) 29.47 (4.81) 8.80 (2.96) 5.67 (0.50) 39.84 (2.88) 45.22 (3.24) 2.13 (0.05)
CCAReg1 S4 77.63 (1.87) 78.68 (1.85) 3.12 (0.68) 2.71 (0.67) 22.80 (1.15) 23.49 (1.43) 2.01 (0.05)
CCAReg4 S4 84.74 (2.12) 83.42 (2.36) 7.09 (2.34) 6.66 (2.28) 13.05 (1.34) 13.68 (1.28) 2.09 (0.06)
FusedCCA1 S4 0.00 (0.00) 0.00 (0.00) 19.51 (2.22) 19.64 (2.53) 30.39 (1.03) 30.55 (1.07) 2.58 (0.06)
FusedCCA4 S4 0.00 (0.00) 0.00 (0.00) 28.76 (2.99) 30.99 (3.34) 23.64 (1.40) 22.43 (1.39) 2.52 (0.05)
BIPnet S5 54.8 (3.64) 50.5 (3.45) 0.19 (0.05) 0.25 (0.06) 60.3 (3.34) 64.42 (2.99) 2.35 (0.21)
BIP S5 55.65 (3) 52.65 (2.96) 0.24 (0.08) 0.32 (0.1) 59.91 (2.77) 62.63 (2.77) 2.64 (0.22)
SELPCCA1 S5 93.40(1.55) 93.30(1.85) 0.06(0.06) 0.00 (0.00) 11.60 (2.52) 11.57 (3.00) 2.72 (0.13)
SELPCCA4 S5 53.10 (6.56) 53.75 (4.26) 8.16 (3.02) 1.84 (1.06) 48.80 (3.35) 58.35 (3.17) 1.81 (0.04)
CCAReg1 S5 88.85 (1.81) 87.95 (1.89) 1.44 (0.52) 1.40(0.50) 19.83 (2.30) 21.51 (2.44) 2.26 (.14)
CCAReg4 S5 78.90 (2.79) 77.65 (2.38) 2.99 (1.26) 2.86 (1.29) 30.01 (1.91) 32.29 (1.66) 1.63 (0.04)
FusedCCA1 S5 0.00 (0.00) 0.00 (0.00) 3.47 (0.81) 2.31 (0.55) 93.89 (1.37) 95.77 (0.97) 2.72 (0.11)
FusedCCA4 S5 0.00 (0.00) 0.00 (0.00) 7.72 (1.12) 6.31 (1.02) 87.21 (1.62) 89.30 (1.48) 2.01 (0.05)
8.1 Sensitivity results
We assess the impact of the choice of hyperparameters qν on the posterior inference as
follows. We applied our BIPnet method at a range of values to data generated from settings
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1 and 5 described in the main manuscript. We repeated these analysis 20 times (Tables 8.2
and 8.2). We observed negligible variations in our results across all scenarios. However,
in setting 5 in particular, higher values of qν increased the number of false positive and
decreased the number of false negative. From tables 8.4 and 8.5, when r is larger, while
the MSE is worst, the variable selection performance is getting better in setting 5.
Table 8.2: BIPnet: Sensitivity results for the hyperparameter q, the prior probability for
variable selection. S1 stands for setting 1, S5 stands for setting 5, FNR1 stands for false
negative rate for X1, FPR1; false positive rate for X1. F11 is F-measure for X1. AUC1
is the area under the ROC curve to assess variable selection for X1.
Setting qν FNR1 FPR1 F11 AUC1
S1 0.025 0 (0) 0.03 (0.02) 99.94 (0.04) 1 (0)
S1 0.05 0 (0) 0.08 (0.05) 99.84 (0.09) 1 (0)
S1 0.1 0 (0) 0.21 (0.09) 99.59 (0.18) 1 (0)
S1 0.2 0 (0) 4.1 (1.36) 93.41 (2.09) 1 (0)
S5 0.025 61.17 (3.5) 0.01 (0.01) 54.16 (3.72) 0.88 (0.02)
S5 0.05 65.85 (3.03) 0.07 (0.03) 49.34 (3.45) 0.82 (0.02)
S5 0.1 43.39 (3.54) 0.25 (0.08) 70.48 (3.07) 0.84 (0.01)
S5 0.2 32.81 (3.73) 8.55 (1.78) 66.01 (2.02) 0.81 (0.02)
Table 8.3: BIPnet: Sensitivity results for the hyperparameter q, the prior probability for
variable selection. S1 stands for setting 1, S5 stands for setting 5, FNR2 stands for false
negative rate for X2, FPR2; false positive rate for X2. F12 is F-measure for X2. AUC2
is the area under the ROC curve to assess variable selection for X2. MSE is mean square
error.
Setting qν FNR2 FPR2 F12 AUC2 MSE
S1 0.025 0 (0) 0.03 (0.03) 99.94 (0.05) 1 (0) 1.92 (0.04)
S1 0.05 0 (0) 0.04 (0.02) 99.92 (0.04) 1 (0) 1.91 (0.03)
S1 0.1 0 (0) 0.24 (0.1) 99.54 (0.2) 1 (0) 2.43 (0.34)
S1 0.2 0 (0) 0.96 (0.28) 98.17 (0.51) 1 (0) 1.92 (0.03)
S5 0.025 68.25 (2.86) 0.08 (0.07) 46.85 (3.19) 0.88 (0.02) 3.72 (0.23)
S5 0.05 64.09 (2.5) 0.05 (0.03) 51.83 (2.64) 0.83 (0.02) 3.44 (0.17)
S5 0.1 46.55 (3.37) 0.3 (0.09) 67.84 (2.92) 0.85 (0.01) 3.07 (0.11)
S5 0.2 30.18 (3.19) 9.4 (1.97) 67.22 (2.51) 0.83 (0.02) 3.02 (0.11)
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Table 8.4: BIPnet: Sensitivity results for r, the number of components. S1 stands for
setting 1, S5 stands for setting 5, FNR1 stands for false negative rate for X1, FPR1; false
positive rate for X1. F11 is F-measure for X1. AUC1 is the area under the ROC curve to
assess variable selection for X1.
Setting r FNR1 FPR1 F11 AUC1
S1 3 0 (0) 0.03 (0.02) 99.94 (0.04) 1 (0)
S1 4 0 (0) 0.08 (0.05) 99.84 (0.09) 1 (0)
S1 6 0 (0) 0.08 (0.05) 99.84 (0.09) 1 (0)
S1 8 0 (0) 0.18 (0.07) 99.64 (0.14) 1 (0)
S5 3 70.94 (1.54) 0.01 (0.01) 44.62 (1.78) 0.82 (0.02)
S5 4 65.85 (3.03) 0.07 (0.03) 49.34 (3.45) 0.82 (0.02)
S5 6 63.63 (2.47) 0.12 (0.07) 52.28 (2.61) 0.93 (0.01)
S5 8 50.99 (4.9) 0.37 (0.16) 62.49 (3.96) 0.96 (0.01)
Table 8.5: BIPnet: Sensitivity results for r, the number of components. S1 stands for
setting 1, S5 stands for setting 5, FNR2 stands for false negative rate for X2, FPR2; false
positive rate for X2. F12 is F-measure for X2. AUC2 is the area under the ROC curve to
assess variable selection for X2. MSE is mean square error.
Setting r FNR2 FPR2 F12 AUC2 MSE
S1 3 0 (0) 0.01 (0.01) 99.97 (0.03) 1 (0) 1.95 (0.06)
S1 4 0 (0) 0.04 (0.02) 99.92 (0.04) 1 (0) 1.91 (0.03)
S1 6 0 (0) 0.18 (0.08) 99.65 (0.16) 1 (0) 2.2 (0.2)
S1 8 0 (0) 0.14 (0.07) 99.73 (0.13) 1 (0) 1.96 (0.04)
S5 3 69.24 (2.41) 0.03 (0.02) 46.07 (2.69) 0.81 (0.02) 3.81 (0.28)
S5 4 64.09 (2.5) 0.05 (0.03) 51.83 (2.64) 0.83 (0.02) 3.44 (0.17)
S5 6 50.82 (5.16) 0.21 (0.1) 62.5 (4.55) 0.95 (0.01) 6.14 (1.72)
S5 8 42.4 (5.27) 0.34 (0.12) 69.66 (4.33) 0.95 (0.01) 5.37 (1.99)
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9 Grouping information of genes and SNPs
Table 9.1: List of genes within each IPA gene network. Gene names in bold face have the
highest averaged MPPs (>0.85) across the 20 random splits.
Network # Gene lists
1 BSG;CPM;FBXO7;KCTD12;LGALS3BP;LRRC37B;MPG;MRPL18;MRPL22;NAMPT;NEK4;NKD2;NOL7
PEG10;RAB7A;RAD18;RBM39;RPL35;RPS23;RPS29;RPS3;RPS4X;TMED3;TRIM8;UBE2A;VHL;XKR8
2 ALDH7A1;CARD6;CRTAP;CSTB;DTX3;EDA;EDARADD;EMP3;FBXL16;GIMAP5;GPM6A;GRN;MEFV;
PCDHAC2;PI3;RAB10;RAB11FIP5;RAB37;RAB3C;RAB8A;RFTN1;SEC11C;SLPI;SPEF2;SPG11;ST3GAL5
TMOD2;TPMT;ZNF274
3 ACP2;ATF7;BCLAF1;CCND1;CMAS;CTSE;CTSH;DAZ2;DCTD;DDX46;EEF1B2;EIF5A2;GPBAR1
HACE1;HDX;KIF4A;LUC7L;LUC7L2;NCAPD3;NIF3L1;TBC1D7;TRPM8;ULK2;UTP6;ZNF181
4 ABI3;APIP;ATXN7L2;CCDC82;CHGA;CHGB;CLPTM1L;DSE;ENY2;GNG10;GNG4;GRK4;HOMER2;
HOMER3;ITPR3;MAK;MAPK1;NEIL3;NEK2;NR2C1;PATL1;RGS8;RSBN1;RSBN1L;SCG3;SPTBN4
5 ANGPTL3;BCHE;BRMS1L;CBX8;CHST12;CHST5;DPEP2;FBXO2;FUZ;GCKR;HS6ST3;LY86;LY96
MARVELD3;MCOLN3;MID2;NOVA1;PNOC;PON2;RBP1;SLC12A9;SULT1C3;TNFAIP8L1;ZNF526;ZNF785
6 ANKRD34A;ATP13A1;CCDC136;DCLK1;FARP2;GOLM1;LHB;LRRTM1;MAP3K10;NCK1;NUFIP1;NUP62CL
PIGW;PKN2;PNPLA5;PSMF1;RABL2A;RPL14;RPL24;RPL37;SLC13A2;SLC39A4;SNURF;TWISTNB
UBA52;VPS13A;ZNRF4
7 ALG1;ATP11B;DNASE1L1;DNMT3L;FBXO6;GGH;HSPD1;KLF12;MAX;MCM5;MDH1;PASK;PDHA2
PPM1B;RPN2;SCRIB;SDK2;SYNE2;TMEM201;TOMM34;TTC13;VCAM1;YY1
8 ATM;BCL11A;CCNC;CPEB4;CSPP1;DCLRE1C;DHX40;FAM91A1;KLHL26;MED11;MED23;MED31;
MED4;MTHFR;MYH13;NIN;NRBP1;PERP;RASAL1;RIF1;SERPINB9;SYF2;TGIF1;TNRC6B;ZNF592
9 ACTL6A;BCL7A;CCDC71;CPSF6;CPVL;;DDX19A;EDF1;FLII;HIST1H4K;HMGN1;LSAMP;MGMT;MIER2;
MIF4GD;NCOA3;NEGR1;PARP15;PCGF1;PCGF2;PRAME;SFMBT1;SMARCAD1;SPTY2D1;TAF1;UHRF1
10 AKR1A1;BIRC7;BTBD3;CAB39L;CD160;COX4I2;COX5A;COX6B1;COX7A2;COX8C;CYP1B1
GSTT1;HSPB6;HTATIP2;KIF15;MCL1;MGST2;NDUFAF2;NDUFB2;OPTC;SLC15A4
SNRK;STARD9;UQCRQ
11 ADAM19;ADAM2;ALDOC;ASPHD2;BCAN;BTC;CDH2;CNFN;COL19A1;DCN;EN2;ITGB1;METRNL;MME
MMP10;MMP12;MYOCD;PSAP;PYGB;PYGL;RNASE4;ST6GAL1;THBS1;VCAN
12 ARHGAP4;C1QTNF2;CHN2;DEFB110;DEFB114;DEFB126;INSL4;ITLN1;NDE1;NLRC5;OTUD1;
PCSK1N;PRR7;PSMA4;PSMB10;PSMB8;PSMD5;PSMD6;PSMD9;PSME1;RAD23A;TCF7;TSNARE1
13 ABCA8;CHD5;CLGN;CLN5;DGKA;FAM133B;GAA;HEMK1;HIVEP1;LIPH;MEF2A;MTRF1L
MZF1;NAGLU;NCKAP1;NPHP4;SRGAP1;SRGAP3;TIAM2;TNFRSF17;TRMT1;WASF3;ZMAT3
14 ARL4D;CDH13;COL13A1;CRABP2;CST6;CTNNB1;IDI1;LYPD6;MAN2B1;MDN1;PCK1;
POLR3B;PRKCSH;QPCT;RSPO1;SEC31A;SP6;SSH1;SYT12;TBC1D2;UNC13C;ZIC2
15 AIP;ASGR2;CCDC86;CYBA;DIDO1;DNAJC3;DNAJC6;DNAJC9;HABP4;MICB;MT1H;
NADSYN1;PCMT1;PLOD1;SECISBP2;SEPHS2;SHKBP1;TJP2;TMOD1;TPM2
16 ATG2B;B3GALT2;C1QTNF9;CD72;ELK4;IL11RA;IL17RD;IL1RAP;IL1RL2;IL22RA1;
JPH4;MAP3K7;MRS2;MYO10;MYOM1;NCF4;SOCS5;TACC1;TDRD7;TGFBI
17 CAPG;CAPZA3;COL17A1;COL4A3BP;DAG1;EGFLAM;EMILIN1;EMILIN2;ITGA6;ITGA7
KRT18;KRT3;KRT6A;KRT86;MAT1A;PRX;RER1;RFX4;SGCA;TNS1;UCP3;UTRN
Continued on next page
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18 ABAT;ADCY1;ANAPC13;BUB3;CAPN10;CDC26;EIF2B5;FOXE1;FOXK2;HADH;KLF7;
PGM1;RASSF6;SCAMP1;SLC25A27;WDR19
19 ADRA1A;BDKRB2;CCKAR;CCKBR;CCR9;GABBR1;GJC2;GPR157;GPR34;
GPR35;HTR1F;RGS1;RGS11;VN1R1
20 ADCY3;AMOTL2;ARL4C;CLDN23;CSTF3;FIP1L1;FOXA1;GAL;NRG1;PCDHA5;PHF2;
PLCD1;PLEKHG5;PUS7;RAB2A;RAB2B;RAP1GDS1;ROM1;SREBF1;TSC22D3;WDR33;YTHDF2
21 AKR1D1;DERL1;EPHX1;ERBB2;FLT1;KCNA4;KCNAB1;KLF6;KLHL21;LGALS4;MATK;
MRPS21;POLB;RET;RRAS2;SEC61A1;SEC61G;SH2D5;SYK;TYRO3
22 ARNTL2;BLOC1S2;DENND3;DTNBP1;DUSP23;ERMAP;FBXL15;IFI16;KEL;NUDT11;
PPFIA1;PPM1K;PPP1R8;PTPN22;RDM1;RORC;RTP4;SESN3;SLC2A11;SNX20;STAT6
23 AMY2A;APLN;CD33;DIS3;DOC2A;EIF3B;KCNK3;LYL1;MT2A;PHACTR3;
PIK3C3;PTGDS;SH3GLB1;STX8;STXBP3;SYPL1;VAMP8;VPS18;VPS41
24 C6;CDK5RAP3;CR1;ECM2;GFRA1;HPN;KLK1;MAPKAPK5;MS4A1;PAPSS2;
PRELP;PRSS21;SERPINA1;SOS2;SPRED3;STK40;TFPI;THOP1;ZIC3
25 ANG;AP2S1;CD14;CHI3L1;CNR1;CSF3;CXCR4;DYM;FPR2;GIMAP4;GNAI3;GNLY
HRASLS;IRAK3;NECAP2;PLSCR1;REEP6;RTN2;TCN1;TLR6
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Table 9.2: Biological characteristics of IPA gene networks.
Network # Top Diseases and Functions
1 [Cancer, Protein Synthesis, RNA Damage and Repair]
2 [Cell-To-Cell Signaling and Interaction, Dermatological Diseases and Conditions,
Organismal Injury and Abnormalities]
3 [Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking]
4 [Cell Cycle, Endocrine System Disorders, Organismal Injury and Abnormalities]
5 [Auditory and Vestibular System Development and Function, Cellular Development,
Cellular Growth and Proliferation]
6 [Infectious Diseases, Protein Synthesis, RNA Damage and Repair]
7 [Amino Acid Metabolism, Cardiovascular System Development and Function, Cellular Function and Maintenance]
8 [Cell-mediated Immune Response, Cellular Development, Cellular Function and Maintenance]
9 [Cell Cycle, Cellular Assembly and Organization, DNA Replication, Recombination, and Repair]
10 [Cancer, Cell-To-Cell Signaling and Interaction, Inflammatory Response]
11 [Carbohydrate Metabolism, Connective Tissue Development and Function, Tissue Development]
12 [Gene Expression, RNA Damage and Repair, RNA Post-Transcriptional Modification]
13 [Cell Morphology, Cellular Assembly and Organization, Cellular Function and Maintenance]
14 [Cell Cycle, Embryonic Development, Organismal Development]
15 [Connective Tissue Disorders, Dermatological Diseases and Conditions, Developmental Disorder]
16 [Cancer, Cell Signaling, Cell-To-Cell Signaling and Interaction]
17 [Developmental Disorder, Hereditary Disorder, Ophthalmic Disease]
18 [Connective Tissue Disorders, Developmental Disorder, Hereditary Disorder]
19 [Cell Signaling, Cell-To-Cell Signaling and Interaction, Molecular Transport]
20 [Behavior, Hereditary Disorder, Nervous System Development and Function]
21 [Cancer, Gastrointestinal Disease, Organismal Injury and Abnormalities]
22 [Cell Cycle, Cell-To-Cell Signaling and Interaction, Cellular Growth and Proliferation]
23 [Cellular Assembly and Organization, Infectious Diseases, Molecular Transport]
24 [Humoral Immune Response, Inflammatory Response, Neurological Disease]
25 [Cell-To-Cell Signaling and Interaction, Cellular Function and Maintenance,
Hematological System Development and Function]
Table 9.3: List of SNPS with their corresponding genes (or groups). SNP names in bold
face have the highest averaged MPPs (>0.85) across the 20 random splits.
Genes List of SNPs
HDAC9 rs10486302;rs10486301;rs10236525;rs213273;rs213274;rs213276;rs3814991;rs2269749;
rs11764116;rs2249817;rs11768780;rs10248565;rs11984041;rs2074633;rs2023938;rs28688791
ANKS1A rs2273007;rs6918872;rs12205331;rs1737727;rs847851;rs847848;rs7740148;
rs2140418;rs3800435;rs2689088;rs13210323;rs7742443;rs17609940;rs820065
SMG6 rs9914578;rs4790881;rs11658881;rs17761734;rs2281727;rs216172;rs10852932;
rs216219;rs216182;rs1885987;rs216193;rs2224770;rs3760229
P4HA2 rs3761661;rs162887;rs460089;rs460271
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BCAP29 rs10953541;rs3801944;rs10273733
FLT1 rs7326277;rs2296188;rs7987291;rs3794400;rs1408245;rs17625898;rs7995976;rs3751397;
rs7983774;rs9319428;rs9513097;rs9508025;rs9508026;rs2387634;rs10507385;rs9551471;
rs585421;rs748253;rs600640;rs678714;rs9554312
CXCL12 rs2839695;rs2839689;rs10793538;rs11592974;rs7092453;rs17540465;rs2146807;rs928565;
rs1147882;rs266109;rs1147879;rs266108;rs7918568
RASD1 rs711352;rs11545787
RAI1 rs4925102;rs7224617;rs8071107;rs11654482;rs11654526;rs4636969;rs9914733;rs9907986;
rs752579;rs3803763;rs8067439;rs4925112;rs35686634;rs3818717;rs11654081;rs4925114
PHACTR1 rs7768030;rs9357503;rs9349350;rs9296486;rs9296488;rs9381439;rs9296494;rs17617584;
rs1332844;rs7750679;rs9369640;rs6906890;rs10485363;rs1223531;rs9357620;rs4715166
GGCX rs2028898;rs10179904;rs2592551;rs699664;rs762684;rs6738645;rs17026452;rs12714145;rs7568458
VAMP8 rs3755008;rs3731828;rs1058588;rs1010
PLG rs9458011;rs3757019;rs9295131;rs4252109;rs14224;rs783147;rs2295368;rs13231;rs813641;
rs4252159;rs4252170;rs783182;rs783173;rs4252051;rs4252052;rs4252053;rs2314852;rs1950562
PEMT rs16961845;rs4646396;rs750546;rs1531100;rs11658311;rs4646356;rs4244598;rs12325817;rs3760187;rs4646343;rs4646341
COL4A2 rs4773143;rs4773144;rs7986871;rs3809346;rs4773161;rs12876517;rs7319311;rs9515203;rs1927343;
rs1927349;rs7334986;rs60212072;rs7983487;rs7984937;rs7984100;rs7983979;rs4771680;rs7489705;
rs4103;rs59905747;rs45612833;rs7326449;rs4132608;rs56676181;rs75082326;rs76425569;rs3803237;
rs3803236;rs3825490;rs72657953;rs1983931;rs1983932;rs1927350;rs3803232;rs9559814;rs9583500;
rs9515229;rs9559818;rs9301457;rs4773194;rs9521803;rs3803228;rs2296852;rs11839527;rs2296851;
rs413756;rs402661;rs403839;rs2296849;rs421177;rs2274544;rs2391833;rs9559826
EDNRA rs1801708;rs10305860;rs6841473;rs908581;rs2048894;rs5333;rs5334;rs6842241;rs6841581
MRAS rs1199338;rs1199337;rs4678260;rs2347252;rs1720819;rs2306374;rs3732837;rs9818870
UBE2Z rs46522;rs15563;rs1057897
IL6R rs12083537;rs1386821;rs6684439;rs7518199;rs7521458;rs4845622;rs4393147;rs4453032;rs4845623;
rs4537545;rs12730935;rs61812598;rs7529229;rs4845625;rs4845626;rs6689393;rs4129267;rs4845374;
rs2228145;rs11265618;rs10159236;rs10752641;rs4329505;rs6698040;rs4240872;
rs4509570;rs4341355;rs2229238;rs7514452;rs4379670
PLPP3 rs17114036;rs11206831;rs17114046;rs1759752;rs1930760;rs10493211;rs10736393;rs12566304;rs914830
KCNK5 rs10947789;rs2815118
SRR rs408067;rs3744270
ZEB2 rs12105918;rs13382811;rs6755392
PDGFD rs10895547;rs2220377;rs12574463;rs1386751;rs1948122;rs488753;rs7950273
COL4A1 rs681884;rs2275842;rs2275843;rs16975424;rs2298240;rs2298241;rs3742207;rs1213026;rs652572;rs1778817;rs589985;
rs2289800;rs2289799;rs1000989;rs874203;rs874204;rs1975514;rs1562173;rs2305081;rs503053;rs2131939;
rs10492497;rs16975491;rs16975492;rs7329411;rs72654112;rs2305080;rs61749897;rs9521638;rs2241967;
rs683309;rs496916;rs668847;rs668861;rs648263;rs7327728;rs648705;rs648735;rs482757;rs677877;
rs9588116;rs598893;rs7333008;rs7332120;rs7333204;rs645114;rs2166207;rs9521649;rs2166208;
rs76574181;rs9521650;rs41275104;rs41275106;rs12428227;rs494558;rs7987982
SLC22A4 rs35260072;rs3792876;rs3805665;rs3792880;rs3805668;rs13179900;rs270608;rs270607
rs2073838;rs2073839;rs3828673;rs3792885;rs272842;rs3761659;rs3805673;rs273915;rs272893;rs272889
rs272887;rs273909;rs272882;rs272879;rs272873;rs272872;rs2306772;rs1050152
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SLC22A5 rs2631367;rs13180043;rs13180295;rs3788987;rs2631362;rs2631359;rs4646301;rs274571;rs2073642;rs183898
rs17622208;rs4646305;rs274559;rs274558;rs274557;rs2073643;rs274554;rs274553;rs274551;rs274549;rs274547
AL008729.1 rs202072;rs3817737;rs578290
COL4A2-AS2 rs9515217;rs9515218;rs9555703;rs9515219;rs9521781;rs9521782;rs7990214;
rs7990383;rs4773186;rs41275110;rs7992330
TEX41 rs900554;rs11681525;rs786255;rs2381683;rs1371048;rs10496971
MIR3936HG rs2631372;rs4646298;rs2631369;rs2631368
10 Application to the ASCVD data
This Section provides how we pre-process our data and some supplementary materials from
the application of methods to the ASCVD data.
10.1 Data preprocessing
There were 340 patients with gene expression and SNP data, as well as clincal covariates to
calculate their ASCVD score. The proportion of females was 66.47% and that of males was
33.53%; their ages ranged from 40 to 78 with mean age 52.78 years. The following clinical
covariates were added as a third data set: age, gender, BMI, systolic blood pressure, low-
density lipoprotein (LDL), and triglycerides. The gene expression data consisted of 38,624
probes. Genes with variance and entropy expression values that were respectively less than
the 90th and 50th percentile were removed. This resulted in 1,398 genes.
For the SNP data, we started with genes reported by Kullo et al. (2016) that were
found to be associated with ASCVD. We retrieved 1,152 SNPs in these gene regions from
the NCBI dbSNP database but we had data on 718 SNPs, including 22 of the 28 SNPs
reported in Kullo et al. (2016). It should be noted that the remaining SNPs may or may
not be associated with ASCVD. For SNP quality control, we included only SNPs that
had call rate = 100%, were in Hardy-Weinberg equilibrium (P-value ≥ 1 × 10−5), and
had minor allele frequency (MAF) ≥ 1%. At the end of the filtering process, we had 429
SNPs for the analyses. We assumed an additive genetic model in which the genotypes were
coded “0” for non-risk allele homozygotes (alleles with most frequency in our data), “1” for
heterozygotes, and “2” for risk-allele homozygotes (minor alleles). We treated the genetic
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data as continuous. The gene expression and SNP data were each standardized to have
mean zero and standard deviation one for each feature.
Figure 10.1: Marginal posterior probabilities of genes for each the of the 4 components
using method BIPnet+Cov for a random split.
Figure 10.2: Marginal posterior probabilities of SNPs for each the of the 4 components
using method BIPnet+Cov.
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Figure 10.3: Marginal posterior probabilities of IPA gene networks (from component 1)
using method BIPnet+Cov.
Figure 10.4: Marginal posterior probabilities of SNP groups (i.e genes) using method BIP-
net+Cov. The plots on the left and right are the MPPs from component 3 and 4 respec-
tively.
References
AHA (2016). Cardiovascular disease: A costly burden for America projections
through 2035, Accessed December 21, 2019. http://www.heart.org/idc/groups/
45
heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf.
Bartels, S., A. R. Franco, and T. Rundek (2012). Carotid intima-media thickness (cimt)
and plaque from risk assessment and clinical use to genetic discoveries. Perspectives in
Medicine 1 (1–12), 139 – 145. New Trends in Neurosonology and Cerebral Hemodynamics
– an Update.
Benson, M. D., Q. Yang, D. Ngo, Y. Zhu, D. Shen, L. A. Farrell, S. Sinha, M. J. Keyes,
R. S. Vasan, M. G. Larson, J. G. Smith, T. J. Wang, and R. E. Gerszten (2018). Genetic
architecture of the cardiovascular risk proteome. Circulation 137 (11), 1158–1172.
Chalise, P., D. C. Koestler, M. Bimali, Q. Yu, and B. L. Fridley (2014, 06). Integrative clus-
tering methods for high-dimensional molecular data. Translational cancer research 3 (3),
202–216.
Chekouo, T., F. C. Stingo, J. D. Doecke, and K.-A. Do (2017). A Bayesian integrative
approach for multi-platform genomic data: A kidney cancer case study. Biometrics 73 (2),
615–624.
Chen, R.-B., C.-H. Chu, S. Yuan, and Y. N. Wu (2016). Bayesian sparse group selection.
Journal of Computational and Graphical Statistics 25 (3), 665–683.
Gottardo, R. and A. E. Raftery (2008). Markov chain Monte Carlo with mixtures of mu-
tually singular distributions. Journal of Computational and Graphical Statistics 17 (4),
949–975.
Hoeting, J. A., D. Madigan, A. E. Raftery, and C. T. Volinsky (1999). Bayesian model
averaging: A tutorial. Statistical Science 14 (4), 382–401.
Kan, M., S. Shan, H. Zhang, S. Lao, and X. Chen (2015). Multi-view discriminant analysis.
IEEE transactions on pattern analysis and machine intelligence 38 (1), 188–194.
Klami, A., S. Virtanen, and S. Kaski (2013). Bayesian canonical correlation analysis.
Journal of Machine Learning Research 14 (1), 965–1003.
46
Kullo, I. J., H. Jouni, E. E. Austin, S.-A. Brown, T. M. Kruisselbrink, I. N. Isseh, R. A.
Haddad, T. S. Marroush, K. Shameer, J. E. Olson, U. Broeckel, R. C. Green, D. J.
Schaid, V. M. Montori, , and K. R. Bailey (2016). Incorporating a genetic risk score
into coronary heart disease risk estimates: Effect on ldl cholesterol levels (the migenes
clinical trial). Circulation 133, 1181–1188.
Li, J., S. Wang, J. Bai, X.-L. Yang, Y.-L. Zhang, Y.-L. Che, H.-H. Li, and Y.-Z. Yang
(2018). Novel role for the immunoproteasome subunit psmb10 in angiotensin ii–induced
atrial fibrillation in mice. Hypertension 71 (5), 866–876.
Li, Q. and L. Li (2018). Integrative linear discriminant analysis with guaranteed error rate
improvement. Biometrika 105 (4), 917–930.
Lock, E. F., K. A. Hoadley, J. S. Marron, and A. B. Nobel (2013, 03). Joint and individual
variation explained (JIVE) for integrated analysis of multiple data types. The annals of
applied statistics 7 (1), 523–542.
Luo, C., J. Liu, D. K. Dey, and K. Chen (2016). Canonical variate regression. Biostatis-
tics 17 (3), 468–483.
Mo, Q., R. Shen, C. Guo, M. Vannucci, K. S. Chan, and S. G. Hilsenbeck (2018). A fully
Bayesian latent variable model for integrative clustering analysis of multi-type omics
data. Biostatistics (Oxford, England) 19 (1), 71–86.
Qiu, Y.-Q. (2013). KEGG Pathway Database, pp. 1068–1069. New York, NY: Springer
New York.
Rockova, V. and E. Lesaffre (2014, 03). Incorporating grouping information in Bayesian
variable selection with applications in genomics. Bayesian Anal. 9 (1), 221–258.
Safo, E. S., J. M. Eun, and H. Lillian (2019). Sparse linear discriminant analysis for
multi-view structured data. https://arxiv.org/abs/1911.05643 .
47
Safo, S. E., J. Ahn, Y. Jeon, and S. Jung (2018). Sparse generalized eigenvalue problem
with application to canonical correlation analysis for integrative analysis of methylation
and gene expression data. Biometrics 74 (4), 1362–1371.
Safo, S. E., S. Li, and Q. Long (2018, 03). Integrative analysis of transcriptomic and
metabolomic data via sparse canonical correlation analysis with incorporation of biolog-
ical information. Biometrics 74 (1), 300–312.
Shaw, S. G., D. J. Abraham, D. M. Baker, and J. Tsui (2012). Cell signalling pathways
leading to novel therapeutic strategies in cardiovascular disease. Cardiology research and
practice 2012, 475094–475094.
Shen, R., A. B. Olshen, and M. Ladanyi (2009). Integrative clustering of multiple genomic
data types using a joint latent variable model with application to breast and lung cancer
subtype analysis. Bioinformatics 25 (22), 2906–2912.
Shen, R., S. Wang, and Q. Mo (2013, 04). Sparse integrative clustering of multiple omics
data sets. The annals of applied statistics 7 (1), 269–294.
van Dyk, D. A. and T. Park (2008). Partially collapsed Gibbs samplers. Journal of the
American Statistical Association 103 (482), 790–796.
Wang, Z. V. and J. A. Hill (2015). Protein quality control and metabolism: bidirectional
control in the heart. Cell metabolism 21 (2), 215–226.
Witten, D. M., R. Tibshirani, and T. Hastie (2009). A penalized matrix decomposition,
with applications to sparse principal components and canonical correlation analysis. Bio-
statistics 10 (3), 515–534.
Witten, D. M. and R. J. Tibshirani (2009). Extensions of sparse canonical correlation
analysis with applications to genomic data. Statistical Applications in Genetics and
Molecular Biology 8.
48
